```
                  in Derwent Patent Files
 NEWS  6  Oct 27  Elsevier Key Serials Dictionary and Echoing added to
                  Derwent Subscriber Files WPIDS and WPIX
 NEWS  7  Nov 29  Derwent announces further increase in updates for DWPI
 NEWS  8  Dec  5  French Multi-Disciplinary Database PASCAL Now on STN
 NEWS  9  Dec  5  Trademarks on STN - New DEMAS and EUMAS Files
 NEWS 10  Dec 15  2001 STN Pricing
 NEWS 11  Dec 17  Merged CEABA-VTB for chemical engineering and
                  biotechnology
 NEWS 12  Dec 17  Corrosion Abstracts on STN
 NEWS 13  Dec 17  SYNTHLINE from Prous Science now available on STN
 NEWS 14  Dec 17  The CA Lexicon available in the CAPLUS and CA files
 NEWS 15  Jan 05  MEDSLINE is being removed from STN
 NEWS 16  Feb 06  Engineering Information Encompass files have new names
 NEWS 17  Feb 16  TOXLINE no longer being updated

 NEWS EXPRESS  FREE UPGRADE 5.0e FOR STN EXPRESS 5.0 WITH DISCOVER!
               (WINDOWS) NOW AVAILABLE
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:04:40 ON 02 APR 2001

=> file reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.15       0.15

FILE 'REGISTRY' ENTERED AT 13:04:49 ON 02 APR 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:    1 APR 2001  HIGHEST RN 329683-87-6
DICTIONARY FILE UPDATES:   1 APR 2001  HIGHEST RN 329683-87-6

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Structure search limits have been increased.  See HELP SLIMIT
for details.

=> s pagoclone/cn
L1             1 PAGOCLONE/CN
```

```
=> file bioscienc
FILE 'DRUGMONOG' . CESS NOT AUTHORIZED
COST IN U.S. DOL  3                                    SINCE FILE      TOTAL
                                                         ENTRY     SESSION
FULL ESTIMATED CO                                         4.11        4.26

FILE 'ADISALERTS'  TERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 200  dis International Ltd. (ADIS)

FILE 'ADISINSIGHT  NTERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 200  dis International Ltd. (ADIS)

FILE 'AGRICOLA' E  RED AT 13:05:10 ON 02 APR 2001

FILE 'ANABSTR' EN  ED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (c) 20  HE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' E  ED AT 13:05:10 ON 02 APR 2001
(c) 2001 FAO (on  alf of the ASFA Advisory Board) All rights reserved.

FILE 'BIOBUSINES  NTERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20  iological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERC  NTERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20  ioCommerce Data Ltd. Richmond Surrey, United Kingdom. All
rights reserved

FILE 'BIOSIS' EN  D AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20  IOSIS(R)

FILE 'BIOTECHABS  CESS NOT AUTHORIZED

FILE 'BIOTECHDS'  ERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20  ERWENT INFORMATION LTD

FILE 'BIOTECHNO'  ERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20  lsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTE  AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20  AB INTERNATIONAL (CABI)

FILE 'CANCERLIT'  RED AT 13:05:10 ON 02 APR 2001

FILE 'CAPLUS' ENT  D AT 13:05:10 ON 02 APR 2001
USE IS SUBJECT T  TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELI  ETERMS" FOR DETAILS.
COPYRIGHT (C) 20  ERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB'  ERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (c) 20  ECHEMA eV

FILE 'CEN' ENTER  T 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20  erican Chemical Society (ACS)

FILE 'CIN' ENTE  13:05:10 ON 02 APR 2001
USE IS SUBJECT  . TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP  ETERMS" FOR DETAILS.
COPYRIGHT (C) 20  erican Chemical Society (ACS)
```

FILE 'CONFSCI' E D AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(mbridge Scientific Abstracts (CSA)

FILE 'CROPB' ENT. AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(RWENT INFORMATION LTD

FILE 'CROPU' ENTE AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20(RWENT INFORMATION LTD

FILE 'DDFB' ACCE T AUTHORIZED

FILE 'DDFU' ACCE OT AUTHORIZED

FILE 'DGENE' ENT AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20 ERWENT INFORMATION LTD

FILE 'DRUGB' ENT AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(RWENT INFORMATION LTD

FILE 'DRUGLAUNCH ERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20(SWORLD Publications Ltd

FILE 'DRUGMONOG2 ERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(SWORLD Publications Ltd

FILE 'DRUGNL' EN D AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(SWORLD Publications Ltd

FILE 'DRUGU' ENT AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20(RWENT INFORMATION LTD

FILE 'DRUGUPDATE TERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(SWORLD Publications Ltd

FILE 'EMBAL' ENT AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(sevier Science B.V. All rights reserved.

FILE 'EMBASE' E D AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 20(sevier Science B.V. All rights reserved.

FILE 'ESBIOBASE' RED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(sevier Science B.V., Amsterdam. All rights reserved.

FILE 'FOMAD' ENT AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(atherhead Food Research Association

FILE 'FOREGE' E D AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(atherhead Food Research Association

FILE 'FROSTI' E AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2 atherhead Food Research Association

FILE 'FSTA' ENT T 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2 ternational Food Information Service

FILE 'GENBANK' E D AT 13:05:10 ON 02 APR 2001

FILE 'HEALSAFE' ED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2 mbridge Scientific Abstracts (CSA)

FILE 'IFIPAT' E) AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(FI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLU :TERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(apan Science and Technology Corporation (JST)

FILE 'KOSMET' EN) AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(nternational Federation of the Societies of Cosmetics
Chemists

FILE 'LIFESCI' E :D AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2('ambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' RED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (c) 2(AIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' E ED AT 13:05:10 ON 02 APR 2001

FILE 'NIOSHTIC' RED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTE AT 13:05:10 ON 02 APR 2001
Compiled and dis ted by the NTIS, U.S. Department of Commerce.
It contains copy ed material.
All rights rese (2001)

FILE 'OCEAN' EN AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(mbridge Scientific Abstracts (CSA)

FILE 'PASCAL' EN) AT 13:05:10 ON 02 APR 2001
Any reproductio issemination in part or in full,
by means of any ss and on any support whatsoever
is prohibited w the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2(NIST-CNRS. All rights reserved.

FILE 'PHAR' ENT AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(JB Publications Ltd. (PJB)

FILE 'PHIC' ENTE AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(B Publications Ltd. (PJB)

FILE 'PHIN' ENT AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(JB Publications Ltd. (PJB)

FILE 'PROMT' EN AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(le Group. All rights reserved.

FILE 'SCISEARCH' RED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2(stitute for Scientific Information (ISI) (R)

FILE 'SYNTHLINE' ERED AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2. ous Science

FILE 'TOXLINE' E ED AT 13:05:10 ON 02 APR 2001

FILE 'TOXLIT' EN) AT 13:05:10 ON 02 APR 2001

```
FILE 'USPATFULL'      ERED AT 13:05:10 ON 02 APR 2001
CA INDEXING COP       T (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' EN       AT 13:05:10 ON 02 APR 2001
COPYRIGHT (C) 2       ERWENT INFORMATION LTD

FILE 'WPINDEX' ;      S NOT AUTHORIZED

=> s l1 or pagoc      or (rp 59037) or (rp 62955)
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
  13 FILES SEAR       ..
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
  27 FILES SEAR       ..
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
'CN' IS NOT A V       FIELD CODE
  45 FILES SEAR       ..
'CN' IS NOT A V       FIELD CODE
L2          152       PAGOCLONE OR (RP 59037) OR (RP 62955)

=> duplicate
ENTER REMOVE, I       Y, ONLY, OR (?):remove
ENTER L# LIST (       ):l2
DUPLICATE IS NO       LABLE IN 'ADISINSIGHT, BIOCOMMERCE, DGENE, DRUGLAUNCH,
DRUGMONOG2, DRU       ES, FOREGE, GENBANK, KOSMET, MEDICONF, PHAR, SYNTHLINE'.
ANSWERS FROM TH       LES WILL BE CONSIDERED UNIQUE
DUPLICATE PREFE       IS 'ADISALERTS, ADISINSIGHT, BIOCOMMERCE, BIOSIS,
BIOTECHNO, CAPL       ABA-VTB, CIN, DRUGNL, DRUGU, DRUGUPDATES, EMBASE,
MEDLINE, PASCAL,      , PHIN, PROMT, SCISEARCH, TOXLINE, TOXLIT, USPATFULL'
KEEP DUPLICATES       MORE THAN ONE FILE?  Y/(N):n
PROCESSING COM        FOR L2
L3          13        CATE REMOVE L2    (22 DUPLICATES REMOVED)

=> s stutter? (       ch dysfluen? or dysarthr? or speech block? or logospasm
or tourette
  17 FILES SEA        ..
  30 FILES SEAR       ..
  45 FILES SEA        ..
L4        32929       R? OR SPEECH DYSFLUEN? OR DYSARTHR? OR SPEECH BLOCK? OR
                      ASM OR TOURETTE

=> s l3 and l4
  29 FILES SEA        .
L5            2         L4
```

```
=> d ibib abs
```

L5 ANSWER 1 C… APLUS COPYRIGHT 2001 ACS
ACCESSION NUMB… 2001:100965 CAPLUS
DOCUMENT NUMBE… 134:141757
TITLE: Methods and compositions using GABA receptor modulators for alleviating **stuttering**
INVENTOR(S): Murphy, John J.; D'orlando, Kay Jorgenson
PATENT ASSIGNEE… Interneuron Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NU… CT: 1
PATENT INFORMA…

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200100…	A2	20010208	WO 2000-US20402	20000727

W: AE… AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, … DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, … IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, … MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, … SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, … AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, … KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, … ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, … CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. … : US 1999-362691 19990729
OTHER SOURCE(S… MARPAT 134:141757

AB Methods o… …ing **stuttering** include treating people with .gamma.-a… …yric acid (GABA) receptor modulators, including cyclopyrr… . A second active agent may be used with GABA receptor modulator… …ive enantiomers, active metabolites, and pharmaceutically acceptabl… … of GABA receptor modulators, including cyclopyrrolones, are accep… …mponents of the compns. The cyclopyrrolone class of modulators … …des **pagoclone**, suriclone, zopiclone, 2-(7-chlo… …hthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one, 2-(7… …-2-naphthyridin-1,8-yl)isoindolin-1-yl-4-acetamido… …, and 2-(7-chloro-1,8-naphthyridin-2yl)-3-(5-methyl-5-hydroxy-2… …yl)-1-isoindolinone.

TI Methods a… …positions using GABA receptor modulators for alleviating **stutterin…**

AB Methods o… …ing **stuttering** include treating people with .gamma.-a… …yric acid (GABA) receptor modulators, including cyclopyrr… . A second active agent may be used with GABA receptor modulator… …ve enantiomers, active metabolites, and pharmaceutically acceptabl… …of GABA receptor modulators, including cyclopyrrolones, are accep… …mponents of the compns. The cyclopyrrolone class of modulator… …es **pagoclone**, suriclone, zopiclone, 2-(7-chlo… …hthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one, 2-(7… …-2-naphthyridin-1,8-yl)isoindolin-1-yl-4-acetamido… …, and 2-(7-chloro-1,8-naphthyridin-2yl)-3-(5-methyl-5-hydroxy-2… …yl)-1-isoindolinone.

ST GABA rece… …ulator **stuttering** treatment; cyclopyrrolone compd **stu… …treatment**

IT Drug deli… …tems
(GABA … modulators for alleviating **stuttering**)

IT GABA rec…
RL: BPR … process); BSU (Biological study, unclassified); BIOL

(Biologic ; PROC (Process)
(GABA modulators for alleviating **stuttering**)
IT GABA ago
(GABA ; eceptor modulators for alleviating **stuttering**)
IT GABA rec
RL: BPR al process); BSU (Biological study, unclassified); BIOL
(Biologic ; PROC (Process)
(GABA ; eceptor modulators for alleviating **stuttering**)
IT Brain, d
(Gill ourette syndrome; GABA receptor modulators for
allevi uttering)
IT Drug deli tems
(bucca receptor modulators for alleviating **stuttering**)
IT Proteins, c or class
RL: BAC al activity or effector, except adverse); THU
(Therape ; BIOL (Biological study); USES (Uses)
(diaz ng inhibitory protein and fragments; GABA receptor
modula alleviating **stuttering**)
IT Nervous s
(disea ering; GABA receptor modulators for
allevi uttering)
IT Drug deli tems
(epidu A receptor modulators for alleviating **stuttering**
)
IT Drug deli tems
(inject .m.; GABA receptor modulators for alleviating
stutte
IT Drug deli ems
(injec .v.; GABA receptor modulators for alleviating
stutte
IT Drug deli tems
(inje .c.; GABA receptor modulators for alleviating
stutte
IT Drug deli tems
(intra ntricular; GABA receptor modulators for alleviating
stutte
IT Drug deli tems
(intra ABA receptor modulators for alleviating
stutte
IT Behavior
(moto r, motor tic; GABA receptor modulators for alleviating
stutte
IT Drug deli tems
(nasal; eceptor modulators for alleviating **stuttering**)
IT Drug deli ems
(oral; eptor modulators for alleviating **stuttering**)
IT Drug deliv ems
(paren ABA receptor modulators for alleviating
stutte
IT Drug del tems
(recta receptor modulators for alleviating **stuttering**)
IT Disease,
(spee ; GABA receptor modulators for alleviating
stutte
IT Drug deliv ms
(transd BA receptor modulators for alleviating
stutte
IT Drug del tems
(vagi receptor modulators for alleviating **stuttering**
)

IT 50-06-6, P... ...ital, biological studies 50-06-6D, Phenobarbital,
enantio... ...tabolites 53-43-0, Dehydroepiandrosterone 53-43-0D,
Dehydro... ...rone, enantiomers and metabolites 57-43-2,
Amobarbital
57-43-2D, A... ...al, enantiomers and metabolites 57-83-0,
Progestero... ...gical studies 57-83-0D, Progesterone, enantiomers
and
metaboli... ...3, Chlordiazepoxide 58-25-3D, Chlordiazepoxide,
enantiom... ...tabolites 76-73-3, Secobarbital 76-73-3D,
Secobarb... ...iomers and metabolites 76-74-4, Pentobarbitone
76-74-4, ...itone, enantiomers and metabolites 76-75-5,
Thiopen... ...-5D, Thiopental, enantiomers and metabolites 77-02-1,
Aprobarb... ...2-1D, Aprobarbital, enantiomers and metabolites
77-26-9, Bu... ... 77-26-9D, Butalbital, enantiomers and metabolites
115-38-8, ...ital 115-38-8D, Mephobarbital, enantiomers and
metabolite... ...-40-6, Butabarbital 125-40-6D, Butabarbital,
enantiom... ...tabolites 145-13-1, Pregnenolone 145-13-1D,
Pregnenolo... ...iomers and metabolites 151-83-7, Methohexital
151-83-7, ...xital, enantiomers and metabolites 439-14-5, Diazepam
439-14-5D, ..., enantiomers and metabolites 485-49-4, Bicuculline
485-49-4D, ...line, enantiomers and metabolites 516-54-1
516-54-1D, ...mers and metabolites 516-55-2, Allopregnanolone
516-55-2D, ...nanolone, enantiomers and metabolites 567-03-3,
Tetrahydrod... ...ticosterone 567-03-3D, Tetrahydrodeoxycorticosterone,
enantiomers ... ...tabolites 604-75-1, Oxazepam 604-75-1D, Oxazepam,
enantiom... ...tabolites 846-49-1, Lorazepam 846-49-1D, Lorazepam,
enantiom... ...tabolites 846-50-4, Temazepam 846-50-4D, Temazepam,
enantiom... ...tabolites 1005-93-2, Etbicuphat 1005-93-2D,
enantiom... ...tabolites 1134-47-0, .+-.-Baclofen 1134-47-0D,
.+-.-Bac... ...iomers and metabolites 1449-89-4, Mebicyphat
1449-89-4D, ...omers and metabolites 1622-62-4, Flunitrazepam
1622-62-4D, ...azepam, enantiomers and metabolites 2078-54-8,
Propofol ...-8D, Propofol, enantiomers and metabolites 2955-38-6,
Prazepam ...-6D, Prazepam, enantiomers and metabolites 3289-22-3,
Flucyben... ...-3D, enantiomers and metabolites 4406-37-5,
Pregnano... ...-37-5D, Pregnanolone, enantiomers and metabolites
17617-23-1, ...pam 17617-23-1D, Flurazepam, enantiomers and
metaboli... ...-45-7, Picrotoxinin 17617-45-7D, Picrotoxinin,
enantiom... ...tabolites 21416-53-5, Picrotin 21416-53-5D,
Picrotin, e... ...ers and metabolites 23092-17-3, Halazepam
23092-17-3D ...pam, enantiomers and metabolites 23930-19-0
23930-19-0D, ...iomers and metabolites 28911-01-5, Triazolam
28911-01-5D ...lam, enantiomers and metabolites 28981-97-7,
Alprazol... ...-97-7D, Alprazolam, enantiomers and metabolites
29617-43-... ...-43-4D, enantiomers and metabolites 29975-16-4,
Estazol... ...6-4D, Estazolam, enantiomers and metabolites
33125-97-2, ...te 33125-97-2D, Etomidate, enantiomers and
metabol... ...-87-0, Chlorazepam 34985-87-0D, Chlorazepam,
enantiom... ...tabolites 36104-80-0, Camazepam 36104-80-0D,
Camazepam, ...ers and metabolites 36735-22-5, Quazepam
36735-22-5D ...am, enantiomers and metabolites 43200-80-2,
Zopiclone
43200-80-2, ...one, enantiomers and metabolites 51052-72-3,
Isobicyp... ...-72-3D, enantiomers and metabolites 51486-74-9,
Propylb... ...486-74-9D, enantiomers and metabolites 52463-83-9,
Pinazep... ...3-9D, Pinazepam, enantiomers and metabolites
53813-8... ...ne 53813-83-5D, Suriclone, enantiomers and
metabol... ...-90-7, Chlorazepate 57109-90-7D, Chlorazepate,
enantiom... ...abolites 59467-70-8, Midazolam 59467-70-8D,
Midazola... ...ers and metabolites 109370-34-5, Avermectin B

109370-3 -5. . ermectin B, enantiomers and metabolites 117705-18-7
117705-1 -7I . . iomers and metabolites **133737-32-3**,
Pagoclone 1 **2-3D, Pagoclone**, enantiomers
and metabol 133737-48-1 133737-48-1D, enantiomers and metabolites
153046-1 -6 46-19-6D, enantiomers and metabolites 224790-70-9,
Cloflubi yr 790-70-9D, Cloflubicyne, enantiomers and metabolites
224790- -(ythionat 224790-71-0D, Etbicythionat, enantiomers and
metaboli e.
RL: BAC (Bi al activity or effector, except adverse); THU
(Therape ti. ; BIOL (Biological study); USES (Uses)
(GABA re odulators for alleviating **stuttering**)

L5 ANSWER 2 OF LIT
ACCESSION NUMBER 1:3118 TOXLIT
DOCUMENT NUMBER: 134-141757Z
TITLE: ods and compositions using GABA receptor modulators
for
leviating **stuttering**.
AUTHOR: hy JJ; D'orlando KJ
SOURCE: 1). PCT Int. Appl. PATENT NO. 018670 02/08/2001
terneuron Pharmaceuticals, Inc.).
EN: PIXXD2.
PUB. COUNTRY: TED STATES
DOCUMENT TYPE: nt
FILE SEGMENT:
LANGUAGE: lish
OTHER SOURCE: 134:141757
ENTRY MONTH: 03
AB Methods of **stuttering** include treating people with
.gamma.-ami ic acid (GABA) receptor modulators, including
cyclopyrrol second active agent may be used with GABA receptor
modulators. enantiomers, active metabolites, and pharmaceutically
acceptable GABA receptor modulators, including cyclopyrrolones,
are accepta ponents of the compns. The cyclopyrrolone class of
modulators s **pagoclone**, suriclone, zopiclone,
2-(7-chloro hyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-
one, 2-(7-c naphthyridin-1,8-yl)isoindolin-1-yl-4-
acetamic bu , and 2-(7-chloro-1,8-naphthyridin-2yl)-3-(5-methyl-5-
hydroxy- -c)-1-isoindolinone.
TI Methods inc itions using GABA receptor modulators for alleviating
stuttering.
AB Methods of **stuttering** include treating people with
.gamma.-ami ic acid (GABA) receptor modulators, including
cyclopyrrol second active agent may be used with GABA. . .
acceptable GABA receptor modulators, including cyclopyrrolones,
are acceptable onents of the compns. The cyclopyrrolone class of
modulators s **pagoclone**, suriclone, zopiclone,
2-(7-chloro hyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-
one, 2-(7-c -naphthyridin-1,8-yl)isoindolin-1-yl-4-
acetamido bu and 2-(7-chloro-1,8-naphthyridin-2yl)-3-(5-methyl-5-
hydroxy- -c)-1-isoindolinone.
ST GABA rec ator **stuttering** treatment; cyclopyrrolone
compd stutt reatmen

=> s gaba or gam b butyric acid
11 FILES SE R
20 FILES SE R
29 FILES S R
39 FILES S R

```
  52 FILES S   RC
L6       2408   (          GAMMA AMINO BUTYRIC ACID

=> s l6 and
  45 FILES SE RC
L7          1 7 L          1

=> duplicate
ENTER REMOVE, ID       , ONLY, OR (?):remove
ENTER L# LIS   O       L7
DUPLICATE IS   O       BLE IN 'ADISINSIGHT, BIOCOMMERCE, DGENE, DRUGLAUNCH,
DRUGMONOG2,    U       , FOREGE, GENBANK, KOSMET, MEDICONF, PHAR, SYNTHLINE'.
ANSWERS FROM   HE      S WILL BE CONSIDERED UNIQUE
DUPLICATE PR   EE      'ADISALERTS, ADISINSIGHT, BIOSIS, CAPLUS, DRUGB,
DRUGU, EMBAL, EM       BIOBASE, JICST-EPLUS, MEDLINE, PASCAL, PHIN, PROMT,
SCISEARCH, TOXLI       LIT, USPATFULL, WPIDS'
KEEP DUPLICATES        RE THAN ONE FILE?  Y/(N):n
PROCESSING COMPI       R L7
L8                     TE REMOVE L7 (27 DUPLICATES REMOVED)

=> s l6 (s)
  38 FILES SE RC
L9          1 L        1

=> duplicate
ENTER REMOVE, ID       , ONLY, OR (?):remove
ENTER L# LIS   O       :L9
DUPLICATE IS           BLE IN 'ADISINSIGHT, BIOCOMMERCE, DGENE, DRUGLAUNCH,
DRUGMONOG2,    U       , FOREGE, GENBANK, KOSMET, MEDICONF, PHAR, SYNTHLINE'.
ANSWERS FROM   HE      S WILL BE CONSIDERED UNIQUE
DUPLICATE PR   EE      'BIOSIS, CAPLUS, DRUGB, DRUGU, EMBAL, EMBASE,
JICST-EPLUS,   EL      ASCAL, SCISEARCH, TOXLINE, TOXLIT, USPATFULL, WPIDS'
KEEP DUPLICATES        RE THAN ONE FILE?  Y/(N):n
PROCESSING COMPL       R L9
L10           45       TE REMOVE L9 (16 DUPLICATES REMOVED)

=> d ti 1-5

L10  ANSWER 1  O       LUS  COPYRIGHT 2001 ACS
TI   Methods   d       itions using GABA receptor modulators for
     alleviat  g       ring

L10  ANSWER 2  OF      KLIT
TI   Methods   nd      itions using GABA receptor modulators for
     alleviat  g       ring.

L10  ANSWER 3  O       PATFULL
TI     Guani           heterocycle compounds useful as alpha-2 adrenoceptor
       agoni           

L10  ANSWER 4  O       AL COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 1
TI   Baclofe           in Tourette syndrome: A double-blind,
     placebo           , crossover trial.

L10  ANSWER 5          PLUS  COPYRIGHT 2001 ACS        DUPLICATE 2
TI   Treatme           raumatic stress disorder, obsessive-compulsive
disorder
     and rel           ychiatric disorders
```

=> d ti 5-45

L10 ANSWER 5 OF 45 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 2
TI Treatment of traumatic stress disorder, obsessive-compulsive disorder and related psychiatric disorders

L10 ANSWER 6 OF 45 CAPLUS
TI 2-Imidazolinoindole compounds useful as alpha-2 adrenoceptor agonists

L10 ANSWER 7 OF 45 CAPLUS
TI Allelic diagnosis of reward deficiency syndrome and treatment

L10 ANSWER 8 OF 45 CAPLUS
TI 6-(2-Imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists

L10 ANSWER 9 OF 45 CAPLUS
TI 2-Imidazolinobenzoxazole compounds useful as alpha-2 adrenoceptor agonists

L10 ANSWER 10 OF 45 CAPLUS
TI Method for treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists

L10 ANSWER 11 OF 45 IDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Identification of interest and relevance to neurological disorders or dysfunction such as Parkinson's disease involves use of biological array including those associated with neurotransmitter molecules.

L10 ANSWER 12 OF 45 IDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Treating movement disorders using agents which increase GABA-A and decrease NMDA-glutamate neurotransmission.

L10 ANSWER 13 OF 45 BIOBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
TI Reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors.

L10 ANSWER 14 OF 45 BIOSIS COPYRIGHT 2001 BIOSIS
TI Reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors.

L10 ANSWER 15 OF 45 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 3
TI Methods for treating mammals using agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists for treating tardive dyskinesia and other disorders

L10 ANSWER 16 OF 45 MEDLINE
TI Methods for treating mammals using agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists for treating tardive dyskinesia and other disorders.

L10 ANSWER 17 OF 45 CAPLUS
TI 2-Imidazolino heterocyclic compounds useful as alpha-2 adrenoceptor agonists

L10 ANSWER 18 OF 45 CAPLUS

TI 7-(2-[illegible]amino)quinoline compounds useful as alpha-2 adren[illegible]ists

L10 ANSWER [illegible] USPATFULL
TI 2-imi[illegible]o heterocyclic compounds useful as alpha-2 adren[illegible]ists

L10 ANSWER [illegible] USPATFULL
TI 6-(2-[illegible]amino) quinolines useful as alpha-2 adrenoceptor agonis[illegible]

L10 ANSWER [illegible] USPATFULL
TI Use o[illegible] treating psychiatric disorders

L10 ANSWER [illegible] IDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Treatme[illegible]A-uptake related disorders - used for e.g. luster headache[illegible]ti., alcohol withdrawal symptoms, spasticity, growth disturba[illegible]ve dyskinesia or alcohol abuse.

L10 ANSWER [illegible] BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 4
TI Autoanti[illegible]mate decarboxylase in a patient with spinocerebellar degenera[illegible]ogren syndrome.

L10 ANSWER [illegible] ASCAL COPYRIGHT 2001 INIST-CNRS. ALL RIGHTS RESERVED.
TIEN Associ[illegible]a Tourette-like syndrome with ofloxacin

L10 ANSWER [illegible] WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Combina[illegible]sugars and amino acids, opt with other drugs - for treatme[illegible]., Alzheimer's disease, depression, hair loss, cancers, hyperten[illegible].

L10 ANSWER 2[illegible] BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 5
TI Neurochem[illegible]nd [illegible]ome related psychopharmacological aspects of Tourette's syndrome.[illegible]date.

L10 ANSWER [illegible] MEDLINE DUPLICATE 6
TI Resoluti[illegible]sa[illegible]thria in multiple sclerosis by treatment with weak electro[illegible]fi[illegible]lds.

L10 ANSWER [illegible] DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Pharmac[illegible]Controversy of CNS Stimulants in Gilles de la Tourette's Syndrom[illegible].

L10 ANSWER [illegible] 5 DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Neurot[illegible]of Beta-Lactam Antibiotics: Predisposing Factors and Pathog[illegible]

L10 ANSWER [illegible] DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Central [illegible]S[illegible]-Effects of Various Antibacterial Compounds.

L10 ANSWER [illegible] DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
TI The Effe[illegible]Different Vigabatrin Treatment Regimens on CSF Biochemistry and Se[illegible]ntrol in Epileptic Patients.

L10 ANSWE[illegible] DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
TI A Case [illegible]ri[illegible]cidemia Type I: Effect of Riboflavin and Carnitine.

L10 ANSWER [illegible] DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Drugs A ' g Mov ment Disorders.

L10 ANSWER 3 BI IS COPYRIGHT 2001 BIOSIS DUPLICATE 7
TI VIGABATRI HE TI EATMENT OF EPILEPSY A DOUBLE-BLIND PLACEBO-CONTROLLED STUDY.

L10 ANSWE 5 DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Anxio

L10 ANSWER 3 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 8
TI Gamma-vi A tr tment of tardive dyskinesia and other movement disorders.

L10 ANSWER 5 PASCAL COPYRIGHT 2001 INIST-CNRS. ALL RIGHTS RESERVED.
TIEN Gamma-v ABA treatment of tardive dyskinesia and other movement disor

L10 ANSWER 3 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 9
TI Progabid e tr tment of hyperkinetic extrapyramidal movement disorder.

L10 ANSWER 3 BIOSIS COPYRIGHT 2001 BIOSIS DUPLICATE 10
TI GLUTARIC- RIA TYPE I PRESENTING WITH HYPOGLYCEMIA.

L10 ANSWER BIOSIS COPYRIGHT 2001 BIOSIS
TI CONCENTR OF GAMMA AMINO BUTYRIC-ACID AND ADENOSINE IN THE CEREBRO SPINAL F PROGRESSIVE MYO CLONUS EPILEPSY WITHOUT LAFORAS BODIES.

L10 ANSWER 5 DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Clonazep Tourette's Syndrome.

L10 ANSWER 4 BIOSIS COPYRIGHT 2001 BIOSIS
TI PHYSIO ICAL CONSIDERATIONS AND A PHARMACOLOGICAL APPROACH IN THE PATHOL HE EXTRAPYRAMIDAL SYSTEM.

L10 ANSWER 5 DRUGB COPYRIGHT 2001 DERWENT INFORMATION LTD
TI CLINICA ARITIES OF THE INITIAL PERIOD OF STUTTERING IN CHILDH ./.

L10 ANSWER 5 DRUGB COPYRIGHT 2001 DERWENT INFORMATION LTD
TI AMINALO W NE OTROPIC AGENT./RUSS./.

L10 ANSWE 5 DRUGU COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Neurotr ters d CNS Disease. Basal Ganglia Disease.

=> d ibib a s -45

L10 ANSWER 1 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:100965 CAPLUS
DOCUMENT NUMBER: 134:141757
TITLE: Methods and compositions using **GABA** receptor modulators for alleviating **stuttering**
INVENTOR(S): Murphy, John J.; D'orlando, Kay Jorgenson
PATENT ASSIGNEE: Interneuron Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 22 pp. CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT:

PATENT INFO

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001(		20010208	WO 2000-US20402	20000727

W: AL, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPI : US 1999-362691 19990729

OTHER SOURCE : ARPAT 134:141757

AB Methods f tir stuttering include treating people with .gamma.- cid (**GABA**) receptor modulators, including cyclopyr cond active agent may be used with GABA receptor modulato tir nantiomers, active metabolites, and pharmaceutically acceptab BA receptor modulators, including cyclopyrrolones, are acce ents of the compns. The cyclopyrrolone class of modulato lud agoclone, suriclone, zopiclone, 2-(7-chloro-2- naphthyr 3-y 3-(5-methyl-2-oxohexyl)isoindolin-1-one, 2-(7-chl aph idin-1,8-yl)isoindolin-1-yl-4-acetamidobutyrate, and

2-(7-chl yridin-2yl)-3-(5-methyl-5-hydroxy-2-oxohexyl)-1-isoindol

TI Methods po ons using **GABA** receptor modulators for alleviat ttering

AB Methods tir uttering include treating people with .gamma.- cid (**GABA**) receptor modulators, including cyclopyr cond active agent may be used with GABA receptor modulato s. nantiomers, active metabolites, and pharmaceutically acceptab e BA receptor modulators, including cyclopyrrolones, are acce nts of the compns. The cyclopyrrolone class of modulato agoclone, suriclone, zopiclone, 2-(7-chloro-2- naphthyr)- -(5-methyl-2-oxohexyl)isoindolin-1-one, 2-(7-chl idin-1,8-yl)isoindolin-1-yl-4-acetamidobutyrate, and

2-(7-chl yridin-2yl)-3-(5-methyl-5-hydroxy-2-oxohexyl)-1-isoindol

ST **GABA** rec or **stuttering** treatment; cyclopyr uttering treatment

IT Drug del
(GABA lators for alleviating **stuttering**
)

IT **GABA** re
RL: BPR ocess); BSU (Biological study, unclassified); BIOL (Biologi C (Process)
(GABA lators for alleviating **stuttering**
)

IT **GABA** agc
(GABA or modulators for alleviating
stutt

IT **GABA** rec
RL: BPR ocess); BSU (Biological study, unclassified); BIOL (Biologi C (Process)
(GABA or modulators for alleviating
stutt

IT Brain, (
(Gil ur tte syndrome; **GABA** receptor
modu viating **stuttering**)
IT Drug del sy
(buc BA tor modulators for alleviating
stutt
IT Prote class
RL: BAC tivity or effector, except adverse); THU
(Therap (Biological study); USES (Uses)
(dia hibitory protein and fragments; **GABA**
rec for alleviating **stuttering**)
IT Nervous
(dise stu g; **GABA** receptor modulators for
alle **ing**)
IT Drug sy
(e GA eptor modulators for alleviating
stut
IT Drug
(in ; **GABA** receptor modulators for alleviating
stut
IT Drug de ms
(inj ; **GABA** receptor modulators for alleviating
stut
IT Drug sy ms
(i ; **GABA** receptor modulators for alleviating
stut
IT Drug de ms
(int cular; **GABA** receptor modulators for
all ing)
IT Drug de ms
(int BA receptor modulators for alleviating
stut
IT Behavi
(m otor tic; **GABA** receptor modulators for
al s ttering**ing**)
IT Drug
(na or modulators for alleviating
stut
IT Drug sy ms
(or re ptor modulators for alleviating
stut
IT Drug sy ms
(p ; GABA receptor modulators for alleviating
stu
IT Drug
(ro tor modulators for alleviating
stut
IT Diseas
(sp orc ; **GABA** receptor modulators for alleviating
st
IT Drug sy ms
(t ; GABA receptor modulators for alleviating
st
IT Drug sy ms
(va ptor modulators for alleviating
stu
IT 50-06- bar tal, biological studies 50-06-6D, Phenobarbital,
enanti d m ab lites 53-43-0, Dehydroepiandrosterone 53-43-0D,
Dehyd os one, enantiomers and metabolites 57-43-2,
Amobarbita

57-43-2D, Amobarbital, enantiomers and metabolites 57-83-0, Progesterone, biological studies 57-83-0D, Progesterone, enantiomers and metabolites 58-25-3, Chlordiazepoxide 58-25-3D, Chlordiazepoxide, enantiomers and metabolites 76-73-3, Secobarbital 76-73-3D, Secobarbital, enantiomers and metabolites 76-74-4, Pentobarbitone 76-74-4D, Pentobarbitone, enantiomers and metabolites 76-75-5, Thiopental 76-75-5D, Thiopental, enantiomers and metabolites 77-02-1, Aprobarbital 77-02-1D, Aprobarbital, enantiomers and metabolites 77-26-9, Butalbital 77-26-9D, Butalbital, enantiomers and metabolites 115-38-8, Mephobarbital 115-38-8D, Mephobarbital, enantiomers and metabolites 125-40-6, Butabarbital 125-40-6D, Butabarbital, enantiomers and metabolites 145-13-1, Pregnenolone 145-13-1D, Pregnenolone, enantiomers and metabolites 151-83-7, Methohexital 151-83-7D, Methohexital, enantiomers and metabolites 439-14-5, Diazepam 439-14-5D, Diazepam, enantiomers and metabolites 485-49-4, Bicuculline 485-49-4D, Bicuculline, enantiomers and metabolites 516-54-1 516-54-1D, enantiomers and metabolites 516-55-2, Allopregnanolone 516-55-2D, Allopregnanolone, enantiomers and metabolites 567-03-3, Tetrahydrodeoxycorticosterone 567-03-3D, Tetrahydrodeoxycorticosterone, enantiomers and metabolites 604-75-1, Oxazepam 604-75-1D, Oxazepam, enantiomers and metabolites 846-49-1, Lorazepam 846-49-1D, Lorazepam, enantiomers and metabolites 846-50-4, Temazepam 846-50-4D, Temazepam, enantiomers and metabolites 1005-93-2, Etbicuphat 1005-93-2D, enantiomers and metabolites 1134-47-0, .+-.-Baclofen 1134-47-0D, .+-.-Baclofen, enantiomers and metabolites 1449-89-4, Mebicyphat 1449-89-4D, enantiomers and metabolites 1622-62-4, Flunitrazepam 1622-62-4D, Flunitrazepam, enantiomers and metabolites 2078-54-8, Propofol 2078-54-8D, Propofol, enantiomers and metabolites 2955-38-6, Prazepam 2955-38-6D, Prazepam, enantiomers and metabolites 3289-22-3, Flucybene 3289-22-3D, enantiomers and metabolites 4406-37-5, Pregnanolone 4406-37-5D, Pregnanolone, enantiomers and metabolites 17617-23-1, Flurazepam 17617-23-1D, Flurazepam, enantiomers and metabolites 17617-45-7, Picrotoxinin 17617-45-7D, Picrotoxinin, enantiomers and metabolites 21416-53-5, Picrotin 21416-53-5D, Picrotin, enantiomers and metabolites 23092-17-3, Halazepam 23092-17-3D, Halazepam, enantiomers and metabolites 23930-19-0 23930-19-0D, enantiomers and metabolites 28911-01-5, Triazolam 28911-01-5D, Triazolam, enantiomers and metabolites 28981-97-7, Alprazolam 28981-97-7D, Alprazolam, enantiomers and metabolites 29617-43-4 29617-43-4D, enantiomers and metabolites 29975-16-4, Estazolam 29975-16-4D, Estazolam, enantiomers and metabolites 33125-97-2, Etomidate 33125-97-2D, Etomidate, enantiomers and metabolites 34985-87-0, Chlorazepam 34985-87-0D, Chlorazepam, enantiomers and metabolites 36104-80-0, Camazepam 36104-80-0D, Camazepam, enantiomers and metabolites 36735-22-5, Quazepam 36735-22-5D, Quazepam, enantiomers and metabolites 43200-80-2, Zopiclone 43200-80-2D, Zopiclone, enantiomers and metabolites 51052-72-3, Isobicyphat 51052-72-3D, enantiomers and metabolites 51486-74-9, Propylbicyphat 51486-74-9D, enantiomers and metabolites 52463-83-9, Pinazepam 52463-83-9D, Pinazepam, enantiomers and metabolites 53813-83-5, Suriclone 53813-83-5D, Suriclone, enantiomers and metabolites 57109-90-7, Chlorazepate 57109-90-7D, Chlorazepate, enantiomers and metabolites 59467-70-8, Midazolam 59467-70-8D, Midazolam, enantiomers and metabolites 109370-34-5, Avermectin B 109370-34-5D, Avermectin B, enantiomers and metabolites 117705-18-7 117705-18-7D, enantiomers and metabolites 133737-32-3, Pagoclone 133737-32-3D, Pagoclone, enantiomers and metabolites 133737-48-1 133737-48-1D, enantiomers and metabolites 153046-19-6 153046-19-6D,

enantiomers and m[illegible]olites 224790-70-9, Cloflubicyne 224790-70-9D, Cloflubicyne, ena[illegible]mers and metabolites 224790-71-0, Etbicythionat 224790-71-0D, Et[illegible]hionat, enantiomers and metabolites
RL: BAC (Biologic[illegible]ctivity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GABA receptor m[illegible]dulators for alleviating **stuttering**
)

L10 ANSWER 2 OF 45 TOXLIT
ACCESSION NUMBER: 20[illegible]:?118 TOXLIT
DOCUMENT NUMBER: C[illegible]-141757Z
TITLE: M[illegible]s and compositions using **GABA** receptor mo[illegible]lators for alleviating **stuttering**.
AUTHOR: Mu[illegible]y JJ; D'orlando KJ
SOURCE: (2 C[illegible]. PCT Int. Appl. PATENT NO. 018670 02/08/2001 (Interneuron Pharmaceuticals, Inc.).
CO[illegible]: PIXXD2.
PUB. COUNTRY: UN[illegible]D STATES
DOCUMENT TYPE: Pa[illegible]
FILE SEGMENT: C[illegible]
LANGUAGE: En[illegible]h
OTHER SOURCE: C[illegible]:141757
ENTRY MONTH: 20[illegible]
AB Methods of treat[illegible] **stuttering** include treating people with .gamma.-aminobuty[illegible] acid (**GABA**) receptor modulators, including cyclopyrrolones. [illegible]econd active agent may be used with **GABA** receptor modulat[illegible]. Active enantiomers, active metabolites, and pharmaceutically [illegible]ptable salts of **GABA** receptor modulators, including cyclop[illegible]ones, are acceptable components of the compns. The cyclopyrrolone cl[illegible] of modulators includes pagoclone, suriclone, zopiclone, 2-(7-chl[illegible]o-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindol[illegible]-one, 2-(7-chloro-2-naphthy[illegible]-1,8-yl)isoindolin-1-yl-4-acetamidobu[illegible]e, and 2-(7-chloro-1,8-naphth[illegible]lin-2yl)-3-(5-methyl-5-hydroxy-2-oxoh[illegible]-1-isoindolinone.
TI Methods and compo[illegible]ons using **GABA** receptor modulators for alleviating **stutt**[illegible]g.
AB Methods of treati[illegible] **stuttering** include treating people with .gamma.-aminobuty[illegible] acid (**GABA**) receptor modulators, including cyclopyrrolones. [illegible]econd active agent may be used with **GABA** receptor modula[illegible]. Active enantiomers, active metabolites, and pharmaceutically [illegible]ptable salts of **GABA** receptor modulators, including cyclop[illegible]ones, are acceptable components of the compns. The cyclopyrrolone c[illegible]of modulators includes pagoclone, suriclone, zopiclone, 2-(7-[illegible]-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindo[illegible]-one,. . .
ST **GABA** receptor mo[illegible]or **stuttering** treatment; cyclopyrrolone c[illegible] stuttering treatmen

L10 ANSWER 3 OF 45 [illegible]FULL
ACCESSION NUMBER: [illegible]1:4769 USPATFULL
TITLE: [illegible]anidinylamino heterocycle compounds useful as alpha-2
[illegible] enoceptor agonists
INVENTOR(S): [illegible]ps, Thomas Lee, Norwich, NY, United States
[illegible]dan, Sophie Eva, Maineville, OH, United States
[illegible]ry, Raymond Todd, Pleasant Plain, OH, United States
[illegible]eldon, Russell James, Fairfield, OH, United States
[illegible]bel, William Lee, Hamilton, OH, United States

PATENT ASSIGNEE(S): es, Jeffrey Joseph, Hamilton, OH, United States
e Procter & Gamble Company, Cincinnati, OH, United ates (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	6172095	20010109	
	9823591	19980604	
APPLICATION INFO.:	1999-308790	19990809	(9)
	1997-US20550	19971121	
		19990809	PCT 371 date
		19990809	PCT 102(e) date

	NUMBER	DATE	
PRIORITY INFORMATION:	1996-31756	19961125	(60)

DOCUMENT TYPE: ent
PRIMARY EXAMINER: man, D. Margaret
LEGAL REPRESENTATIVE: lerman, James C.; Roof, Carl J.
NUMBER OF CLAIMS:
EXEMPLARY CLAIM:
LINE COUNT: 05
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention in lves compounds having the structure (I) as described in the claims, an nantiomers,optical isomers, stereoisomers, diastereomers, ta mers, addition salts, biohydrolyzable amides and esters thereof, a ell as pharmaceutical compositions comprising such novel compounds. e invention also relates to the use of such compounds for preventing or reating disorders modulated by alpha-2 adrenoceptors.
##STR1#

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . to respiratory challenges such as inhaled citric acid. (See, e.g., Callaway, J. R. King, "Effects of Inhaled .alpha.2-Adrenoceptor and GABA.sub.B Receptor Agonists on Citric Acid-Induced Cough and Tidal Volume anges in Guinea Pigs", European Journal of Pharmacology, Vol. 220 (1992),. . . The effectiveness of other alpha-2 agonists the management of neurologic disorders has been demonstrated, including attention-deficit hyperactive disorder and Tourette's syndrome (See, e.g., Chappell P., M. Riddle, L. Scahill, K. Lynch, R. Schultz, A. Amsten, J. Leckman & D. Cohen, "Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience", Journal of American Academy of Child and Adolescent Psychiatry, V (1995), pp. 1140-1146), cognitive disorders. . .

L10 ANSWER 45 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.DUPLICATE 1
ACCESSION NUMBER: 2001 0362 EMBASE Alert (EMBAL)
TITLE: n treatment in Tourette syndrome: A double-blind, -controlled, crossover trial.
AUTHOR: i.S.; Wendlandt J.; Krieger M.; Giuliano J.
CORPORATE : J. Singer, Johns Hopkins Hospital, Harvey 811, 600 N. Street, Baltimore, MD 21287-8811, United States. r@jhmi.edu
SOURCE: ogy, (13 Mar 2001) 56/5 (599-604). Refs: 32. NEURA ISSN: 0028-3878

PUB. COUNT : ite States
DOCUMENT T tic e
LANGUAGE: gli h
SUMMARY LA gli h
AB Objec es igate the effectiveness of baclofen for the treatment
of ti en with **Tourette** syndrome (TS). Background:
Baclo ontains both .gamma.-aminobutyric acid (**GABA**)
and p mine moieties, was suggested in an open-label protocol to
be an treatment for TS. This is a double-blind,
place d study to investigate this medication in children with
TS. M ects received, in a randomized sequence, 4-week
medic of baclofen (20 mg three times daily) and placebo with
a
2-wee g washout period between the cycles. Outcome measures
inclu ical Global Impression (CGI) scale, and the Yale Global
Tic S e (YGTSS), the latter including subscales for total tics
and o rment. Measures were assessed at baseline and on days
28,
42, a study. Results: Ten children (seven boys and three
girls 14) with TS participated. Nine subjects completed the
proto pped out for psychosocial reasons. No major side effects
were e mean change in CGI score (-0.9) after 4 weeks of
baclo t as compared with placebo treatment showed a
significan
impro CI, -1.7 to -0.1; p = 0.04). All subjects showed some
ameli otal YGTSS score during baclofen treatment. The mean
chang GTSS score (-14.7) approached significance (95% CI,
-30.3
to 0. . Examination of differences between baclofen and
placebo
treat expressed as a percent change from baseline showed that
baclo atistically significant effect on both outcome measures.
Subsc YGTSS showed that the reduction in total tic scores was
prima a reduction in the impairment score rather than a
decre . Conclusions: Children with TS may benefit from
treatment
with though improvements may be related to factors other than
tics. ies directly comparing baclofen against other
tic-s gents are recommended.
AB Objec estigate the effectiveness of baclofen for the treatment
of ti en with **Tourette** syndrome (TS). Background:
Baclo ontains both .gamma.-aminobutyric acid (**GABA**)
and p ine moieties, was suggested in an open-label protocol to
be an treatment for TS. This is a double-blind,. . .

L10 ANSWE APLUS COPYRIGHT 2001 ACS DUPLICATE 2
ACCESSION 2000:688058 CAPLUS
DOCUMENT N 133:261534
TITLE: Treatment of post-traumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
INVENTOR(S Fogel, Barry S.
PATENT ASS Synchroneuron, Llc, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT T Patent
LANGUAGE: English
FAMILY ACC T: 1
PATENT INF

PATEN	KIND	DATE	APPLICATION NO.	DATE
WO 20	A2	20000928	WO 2000-US7119	20000317
WO 20	A3	20001228		

W· CH, CN, JP, MX, NZ
R CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,

PRIORITY A : US 1999-273036 19990319

AB The p ntion describes a novel treatment for neuropsychiatric disor ding anxiety disorders, mood disorders, psychotic disor oform disorders, and neuropsychiatric symptoms resulting from sorders. The treatment of the present invention utilizes any a imultaneously act as NMDA-type glutamate receptor antag GABA-A receptor agonists. Preferably these two activities are c ic of a single agent, for example acamprosate (calcium N-ace inate). Alternatively, sep. agents having these activ e combined as a compd. or mixt. and thereby administered toget nvention also provides for a third agent that acts as a non-c MDA-receptor blocking agent or ion channel blocker, that augme ect of the primary treatment. A particularly preferred ion c king agent is magnesium.

IT Brain,
(G **Tourette** syndrome; post-traumatic stress
di essive-compulsive disorder and related neuropsychiatric
di atment with NMDA glutamate antagonists and **GABA**
A

L10 ANSWE , OF USPATFULL
ACCESSION BER: 2000:171042 USPATFULL
TITLE: 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists
INVENTOR(S) Henry, Raymond Todd, Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Seibel, William Lee, Hamilton, OH, United States
PATENT ASS EE(S The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	DATE
PATENT INF MATION	US 6162818	20001219
APPLICATIO INFO.:	US 1999-290731	19990413 (9)
RELATED AP N. INF	Continuation of Ser. No. WO 1997-US20801, filed on 21 Nov 1997	

	NUMBER	DATE
PRIORITY I ORMATI	US 1996-31777	19961111 (60)

DOCUMENT T E: Utility
PRIMARY EX INER: McKane, Joseph K.
ASSISTANT AMINER Oswecki, Jane C.
LEGAL REPR ENTATI Bott, Cynthia M.; Kellerman, James C.; Clark, Karen F.
NUMBER OF AIMS: 42
EXEMPLARY AIM: 1
LINE COUNT: 2524
CAS INDEXI IS AV ABLE FOR THIS PATENT.

AB This invent involves compounds having the following structure:
##S .1## wh ein: a) R.sub.1 is hydrogen; or alkyl; bond (a) is a single
or double nd;

b) R.sub.2 and R.sub.3 are each independently selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl, alkenyl or alkynyl; cycloalkanyl; cycloalkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C.sub.1 -C.sub.3 alkylamino or C.sub.1 -C.sub.3 dialkylamino and halo;

c) R.sub.4, R.sub.5 and R.sub.6 are each independently selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl, alkenyl or alkynyl; cycloalkanyl; cycloalkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C.sub.1 -C.sub.3 alkylamino or C.sub.1 -C.sub.3 dialkylamino; halo; and 2-imidazolinylamino; and wherein one and only one of R.sub.4, R.sub.5 and R.sub.6 is 2-imidazolinylamino;

d) R.sub.7 is selected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C.sub.1 -C.sub.3 alkylamino or C.sub.1 -C.sub.3 dialkylamino and halo;

e) the compound is not 4-(2-imidazolinylamino)indole;

enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, and pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for treating disorders modulated by alpha-2 adrenoceptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . to respiratory challenges such as inhaled citric acid. (See, e.g., Callaway, J. & R. King, "Effects of Inhaled .alpha.2-Adrenoceptor and **GABA**.sub B Receptor Agonists on Citric Acid-Induced Cough and Tidal Volume Changes in Guinea Pigs", European Journal of Pharmacology, Vol. 220 (1992),. . . The effectiveness of other alpha-2 agonists in the management of neurologic disorders has been demonstrated including attention-deficit hyperactive disorder and **Tourette's** syndrome (See, e.g., Chappell P., M. Riddle, L. Scahill, K. Lynch, R. Schultz, A. Arnsten, J. Leckman & D. Cohen, "Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and **Tourette's** syndrome: preliminary clinical experience", Journal of American Academy of Child and Adolescent Psychiatry, Vol. 34 (1995), pp. 1140-1146), cognitive disorders. . .

L10 ANSWER 7 OF 45 USPATFULL

ACCESSION NUMBER:	2000:137814 USPATFULL
TITLE:	Allelic polygene diagnosis of reward deficiency syndrome and treatment
INVENTOR(S):	Blum, Kenneth, San Antonio, TX, United States
PATENT ASSIGNEE(S):	City of Hope National Medical Center, Duarte, CA, United States (U.S. corporation) The University of Texas System AMD Board of Regents, Austin, TX, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6132724	20001017
APPLICATION INFO.:	US 1998-69886	19980429 (9)
DOCUMENT TYPE:	Utility	

PRIMARY EXAMINER: Witz, Jean C.
LEGAL REPRESENTATIV : Hodgins, Daniel S.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 20845

AB Enhancement of attentional processing is attained by administration of an endorphinase inhibitor or enkephalinase inhibitor and optionally, a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalinase releaser, or certain herbal compounds including Rhodiola rosea extract (Pharmaline) and/or Huperzine. These components promote restoration of normal neurotransmitter function and the components combined enhance the release of dopamine at the nucleus accumbens and are non-addictive. Use of the dopamine precursors L-phenylalanine, or L-Tyrosine, the enkephalinase inhibitor D-phenylalanine, and/or the serotonin precursor -hydroxytryptophan and a natural acetylcholenesterase inhibitor and chromium salts (i.e. picolinate, nicotinate, etc.) is especially preferred, but not limited to assist in relieving symptoms associated with brain phenylalanine deficiency.

DETD . . . a number of receptors are involved in various types of substance abuse including dopamine, serotonin, cannabinoid, nitric oxide, nicotinic muscarinic, **GABA**, and others. The diagnosis of Tourette's syndrome is dependent upon the presence of motor tics, and dopamine plays a major role in the regulation of muscle. .

L10 ANSWER 8 OF 45 USPATFULL
ACCESSION NUMBER: 2000:121514 USPATFULL
TITLE: 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
INVENTOR(S): Maurer, Peter J., Cincinnati, OH, United States
Henry, Raymond T., Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6117871	20000912
APPLICATION INFO.:	US 1996-755941	19961125 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-496707, filed on 29 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-169785, filed on 17 Dec 1993, now abandoned	

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Bott, Cynthia M.; Kellerman, James C.; Suter, David L.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1432
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject invention relates to methods of treating alpha-2 adrenoceptor modulated disorders, comprising administration, to a mammal in need of such treatment, of a safe and effective amount of a compound having the following structure: ##STR1## wherein: (a) R is unsubstituted C.sub.1 -C.sub.3 alkanyl or alkenyl; and

(b) ' is se ected from hydrogen; unsubstituted C.sub.1 -C.sub.3 alkanyl
or . kenyl; nsubstituted C.sub.1 -C.sub.3 alkylthio or alkoxy; hydroxy;
thi ; and lo.

The bject nvention also relates compounds and compositions for pre tting treating of disorders modulated by alpha-2 adr .recept rs.

CAS INDEXI IS AV. LABLE FOR THIS PATENT.
DETD . . . to espiratory challenges such as inhaled citric acid. (See, e.g. Calla. , J. & R. King, "Effects of Inhaled .alpha.2-Adrenoceptor and ABA.sub 3 Receptor Agonists on Citric Acid-Induced Cough and idal V me Changes in Guinea Pigs", European Journal of Pha colog Vol. 220 (1992),. . . The effectiveness of other alp -2 ago ts in the management of neurologic disorders has been dem trate including attention-deficit hyperactive disorder and **Tour tte's** drome (See, e.g., Chappell P., M. Riddle, L. Sca l, K. ynch, R. Schultz, A. Arnsten, J. Leckman & D. Cohen, "Gu facine eatment of comorbid attention-deficit hyperactivity dis der an **Tourette's** syndrome: preliminary clinical exp ence", Journal of American Academy of Child and Adolescent Psy iatry, l. 34 (1995), pp. 1140-1146), cognitive disorders. . .

L10 ANSWE OF USPATFULL
ACCESSION BER: 2000:113979 USPATFULL
TITLE: 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
INVENTOR(S : Henry, Raymond Todd, Pleasant Plain, OH, United States
Sheldon, Russell James, Fairfield, OH, United States
Seibel, William Lee, Hamilton, OH, United States
PATENT ASS E(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INF ATIO:	US 6110952	20000829	
	WO 9823611	19980604	
APPLICATIC INFO.:	US 1999-308792	19990809	(9)
	WO 1997-US20803	19971121	
		19990809	PCT 371 date
		19990809	PCT 102(e) date

	NUMBER	DATE
PRIORITY I: HAT A:	US 1996-31787	19961125 (60)

DOCUMENT T :: Utility
PRIMARY EX INER: McKane, Joseph
ASSISTANT INE : Wright, Sonya N
LEGAL REPR ITAT : Kellerman, James C.; Roof, Carl J.
NUMBER OF IMS: 42
EXEMPLARY IM: 1
LINE COUNT 1879
CAS INDEXI IS A ABLE FOR THIS PATENT.
AB Thi ven relateds to compounds of formula I, (2-imi olin ino)benzoxazoles. The compounds have been found to be alp cepto agonists and are useful for treatment of disorders moc lpha-2 adrenoceptors.

CAS INDEXI [illegible] ABLE FOR THIS PATENT.
DETD . [illegible] spiratory challenges such as inhaled citric acid. (See, e.g [illegible], J. & R. King, "Effects of Inhaled .alpha.2-Adrenoceptor and .BA.s [illegible] Receptor Agonists on Citric Acid-Induced Cough and [illegible]me Changes in Guinea Pigs", European Journal of Pha [illegible], Vol. 220 (1992),. . . The effectiveness of other alp [illegible]sts in the management of neurologic disorders has been dem [illegible] including attention-deficit hyperactive disorder and **Tou**[illegible]drome (See, e.g., Chappell P., M. Riddle, L. Sca [illegible]ch, R. Schultz, A. Arnsten, J. Leckman & D. Cohen, "Gu [illegible]atment of comorbid attention-deficit hyperactivity dis [illegible] **Tourette**'s syndrome: preliminary clinical exp [illegible] Journal of American Academy of Child and Adolescent Psy [illegible] 34 (1995), pp. 1140-1146), cognitive disorders. . .

L10 ANSWE [illegible] USPATFULL
ACCESSION [illegible] 2000:54156 USPATFULL
TITLE: Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
INVENTOR(S [illegible] Fogel, Barry S., Waban, MA, United States
PATENT ASS [illegible] Synchroneuron, LLC, Waban, MA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INF [illegible]	US 6057373	20000502
APPLICATIO [illegible]	US 1999-224829	19990104 (9)
RELATED AP [illegible]	Continuation-in-part of Ser. No. US 1997-861801, filed on 22 May 1997, now patented, Pat. No. US 5866585	

DOCUMENT T [illegible] Utility
PRIMARY EX [illegible] MacMillan, Keith D.
ASSISTANT [illegible] Kim, Vickie Y.
LEGAL REPR [illegible] Choate, Hall & Stewart; Pasternack, Sam
NUMBER OF [illegible] 52
EXEMPLARY [illegible] 1
LINE COUNT 1728
CAS INDEXI [illegible] ABLE FOR THIS PATENT.
AB The [illegible]vention describes a novel treatment for movement dis [illegible]rs, including tardive dyskinesia and tardive dystonia, and focal dys [illegible] due to neuroleptics, including blepharospasm, Meige syn [illegible], occupational dystonias. The treatment of the present inv [illegible] izes agents that act as NMDA-type glutamate receptor ant [illegible] The invention also involves the use of an ion channel blo [illegible] to augment the therapeutic action of the drug treatments des [illegible]. Particularly preferred ion channel blocking agent is may [illegible].

CAS INDEXI [illegible] BLE FOR THIS PATENT.
SUMM And [illegible] [illegible]roleptic treatment, clonazepam, a benzodiazepine with **GAB**[illegible] [illegible]tonergic actions, has some efficacy in the tr [illegible] **Tourette**'s syndrome (Steingard et al., J. Am Acad Ch [illegible] Psychiatry, March-April, 33:394-9, 1994). Sedation and at [illegible] [illegible]e dosage of. . .
DETD As [illegible], GA**BA**-A agonists alone are not particularly po [illegible]s of tics. Therefore, NMDA antagonism is likely a nec [illegible] of the therapeutic. . . of memantine is more important
th [illegible] [illegible]ne agonism. Evidence disclosed herein suggests that

mo rs, such as tics and **Tourette**'s, will respond
in lar to tardive movement disorders to drug therapies
ha gonist activity.

L10 ANSW PIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION 001-071285 [08] WPIDS
DOC. NO. 2001-019987
TITLE: dentifying genes of interest and relevance to eurological disorders or dysfunctions such as arkinson's disease involves use of biological array ncluding all genes associated with neurotransmitter olecules.
DERWENT C 04 D16
INVENTOR(REEK, M J; LAFORGE, K S; SPANGLER, R
PATENT AS UYRQ) UNIV ROCKEFELLER
COUNTRY C 3
PATENT IN IC

PATE		ATE	WEEK	LA	PG
WO 2	2	001221 (200108)*		EN	76
R	B	DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ			
	O	SE SL SZ TZ UG ZW			
		AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ			
	E	GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK			
	L	LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG			
	S	TM TR TT TZ UA UG US UZ VN YU ZA ZW			

APPLICATIC AI

PATE	APPLICATION	DATE
WO 2	WO 2000-US16706	20000616

PRIORITY S 1999-334113 19990616
AN 2001- WPIDS
AB WO 2 : 20010207
NOVE Ic ing genetic predisposition to, susceptibility to
deve nt aracteristics of, or persistence of physiological or
path nse to, a neurotransmitter factor-related condition
(NFC dentifying genetic polymorphisms in neurotransmitter
gene ith NFC, using a multiple biological sample array, is
new.
LE RIPTION - An INDEPENDENT CLAIM is also included for
maki) ogical chip plate (I), comprising attaching a wafer
comp urface, a set of probe arrays (II) each comprising a
coll n es, at least two of which, are different, and arranged
in s ed and physically addressable manner, to a body
comp f defined spaces. (II) is selected from a family of
neur enes known to be affected by exposure to addictive
agen hol. The probes are selected from a family of
neur m enes known to be involved in a neurological disorder or
dysf n, nse to strain, stress, gastrointestinal function,
immune
func ive function or signal transduction. The method
comp a material resistant to the flow of a liquid, to
sur arrays, creating test wells.
ing a biological chip plate which is useful for
iden c predisposition to, susceptibility to development of,

char , or persistence of physiological or pathological
resp genetic polymorphisms or gene expression in several
neur nes, preferably opioid system genes, associated with
the plates are useful in prognosis of neurological
disorders
such ac schizophrenia, Tourette syndrome, drug abuse,
attention
defi di anxiety, depression obsessive-compulsive disorder,
stro ob esponse to pain, hypertension, vascular disorders,
migr lzheimer's disease, aggressive behavior, premenstrual
synd neuropathy, suppression of alcohol intake, and
Park e. (All claimed). A DNA array can determine the
part of a pathogenic organism based on characteristic DNA
sequ s rain.
Al he array provides a multifunction analytical
capabilit
as i lo udy of RNA abnormalities or polymorphisms, and
part e nucleotide polymorphisms. It will yield quantitative
infc physiological and/or pathological condition of the
test
subj analysis of the DNA of the subject will provide
infc ng subject genotype and corresponding genetic
pred si methods allow many tests to be set up and processed
toge hey allow much higher throughput of test samples,
these
meth gr rove the efficiency of performing assays on biological
chip logical and genetic conditions can be identified using
the s rapid and inexpensive.
Dwg.
TECH. .
aden DARPP-32, dopamine D1 receptor, dopamine D2 receptor,
and acetylcholine receptor genes such as -E and subtypes,
GABA tyric acid) receptor (muscarinic) genes,
glut e genes, and NMDA (undefined) receptor genes and the
neu ns nes are associated with. . . as opiate, cocaine,
herc ddiction. The neurotransmitter genes are involved in a
neu er such as addiction, schizophrenia, **Tourette**
synd se, attention deficit disorder, anxiety, depression
obse ve disorder, stroke, obesity, response to pain,
hype lar disorders, migraine, nausea,. . .

L10 ANS 2 IDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION BE 00-411597 [35] WPIDS
CROSS RE CE 99-444313 [37]
DOC. NO. '00-124615
TITLE: eating movement disorders using agents which increase
ABA-A neurotransmission and decrease NMDA-glutamate
eurotransmission.
DERWENT C : B06
INVENTOR(EL, B S
PATENT A SY (NC-N) SYNCHRONEURON LLC
COUNTRY (N : 4
PATENT I T

PATI	E	WEEK	LA	PG
WO 2	00525 (200035)*	EN		61
	E DK ES FI FR GB GR IE IT LU MC NL PT SE			
	? MX NZ			
AU 2	00605 (200042)			

APPLICATI . :

PATE)	APPLICATION	DATE
WO 2 .	WO 1999-US27343	19991118
AU 2 1	AU 2000-17347	19991118

FILING DE :

PATE .	PATENT NO
AU 2 .7	ased on WO 200028999

PRIORITY . 1. : 1998-193892 19981118
AN 200C . :PIDS
CR 1999 1
AB WO 2 .B: 20000905
NOVE · l for treating movement disorders comprises administe
an a · 1 . eases GABA-A neurotransmission and decreases
NMD/ :: otransmission to a patient with a movement disorder.
: IPTION - INDEPENDENT CLAIMS are included for:
: r treating movement disorders which comprises
sele " gent (I) that acts as a GABA-A receptor agonist and a
secc , ich acts as a NMDA-type glutamate receptor antagonist
and i them to the patient;
: for assessing risk of developing a neuroleptic or
dopa . blocker-induced movement disorder which comprises
perf .(d tests of total body magnesium status;
: for preventing neuroleptic or dopamine receptor
bloc ' ' ment disorders and for treating movement disorders
whic .' nistering magnesium ions; and
hods/compositions based upon various combinations of
the .
ti-dyskinesia.
ACTION - NMDA Receptor antagonist; GABA-A agonist.
treat simple or multiple tics, **Tourette's**
sync , istonias, blepharospasm and Meige syndrome. The disorders
are ' ed to **GABA** deficiency in the basal ganglia
or t . d excitotoxicity (all claimed). The method may be used
to t kinesia and movement disorders induced by exposure to
neu ' sychotic) drugs.
Dwg.
AB . .
- Ar . .
ACTION - NMDA Receptor antagonist; GABA-A agonist.
treat simple or multiple tics, **Tourette's**
sync onias, blepharospasm and Meige syndrome. The disorders
are ed to **GABA** deficiency in the basal ganglia
or t d excitotoxicity (all claimed). The method may be used
to t kinesia. . .

L10 ANS . ASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
ACCESSIO 04103 EMBASE
TITLE: d deficiency syndrome: A biogenetic model for the

...osis and treatment of impulsive, addictive, and
...sive behaviors.

AUTHOR: ...; Braverman E.R.; Holder J.M.; Lubar J.F.; Monastra
... Miller D.; Lubar J.O.; Chen T.J.H.; Comings D.E.
CORPORATE ... Blum, Department of Biological Sciences, University
...rth Texas, Denton, TX, United States
SOURCE: ...rnal of Psychoactive Drugs, (2000) 32/SUPPL. (1-112).
...s: 638
...N: 0279-1072 CODEN: JPDRD3
COUNTRY: ... States
DOCUMENT ...; General Review
FILE SEGM ... Human Genetics
Clinical Biochemistry
Psychiatry
Drug Literature Index
Drug Dependence, Alcohol Abuse and Alcoholism
LANGUAGE: ...sh
SUMMARY L ...sh.
AB The ...tem, and in particular the dopamine D(2) receptor, has
been ...ward mechanisms. The net effect of neurotransmitter
inte ...solimbic brain region induces 'reward' when dopamine
(DA) ...n the neuron at the nucleus accumbens and interacts
with ... receptor. 'The reward cascade' involves the release
of s ...in turn at the hypothalmus stimulates enkephalin,
whic ...s GABA at the substania nigra, which in
turn ...mount of DA released at the nucleus accumbens or
'rew ...ll known that under normal conditions in the reward
site ...tain our normal drives. In fact, DA has become to be
know ...e molecule' and/or the 'antistress molecule.' When DA
is r ... synapse, it stimulates a number a DA receptors
(D1- ...s in increased feelings of well-being and stress
redu ...n of the literature suggests that when there is a
dysf ...in reward cascade, which could be caused by certain
gene ...genic), especially in the DA system causing a
hypo ..., the brain of that person requires a DA fix to feel
good ...s to multiple drug-seeking behavior. This is so
beca ...ine, heroin, marijuana, nicotine, and glucose all
caus ...neuronal release of brain DA, which could heal the
abno ...rtainly after ten years of study we could say with
conf ...rs of the DAD2 receptor A1 allele have compromised
D(2) ...re lack of D2 receptors causes individuals to have
a hi ...e addictive, impulsive and compulsive behavioral
proc ...severe alcohohsm, cocaine, heroin, marijuana and
nico ...bingeing, pathological gambling, sex addiction,
ADHD ...rome, autism, chronic violence,
post ...disorder, schizoid/avoidant cluster, conduct disorder
and ...r. In order to explain the breakdown of the reward
case ...ltiple genes and environmental stimuli
(pl ...tant aberrant behaviors, Blum united this
hypo ...nder the rubric of a reward deficiency syndrome.
AB ...cade' involves the release of serotonin, which in
turn ... stimulates enkephalin, which in turn inhibits
GABA ...nigra, which in turn fine tunes the amount
of D ...nucleus accumbens or 'reward. . . compulsive
beha ...s, such as severe alcohohsm, cocaine, heroin,

mari…e, glucose bingeing, pathological gambling, sex
addi… …e s Syndrome, autism, chronic violence,
pos… …rder, schizoid/avoidant cluster, conduct
disorder
and … In order to explain the. . .

L10 ANS… ; COPYRIGHT 2001 BIOSIS
ACCESSIO… 76 BIOSIS
DOCUMENT … 054076
TITLE: … iciency syndrome: A biogenetic model for the
… and treatment of impulsive, addictive, and
… behaviors.
AUTHOR(S): …eth (1); Braverman, Eric R.; Holder, Jay M.;
… F.; Monastra, Vincent J.; Miller, David;
Lubar,
…; Chen, Thomas J. H.; Comings, David E.
CORPORATE … rtment of Biological Sciences, University of North
… ton, TX USA
SOURCE: … Psychoactive Drugs, (November, 2000) Vol. 32,
… ment, pp. i-iv, 1-112. print.
… -1072.
DOCUMENT … view
LANGUAGE:
SUMMARY …
AB The … , and in particular the dopamine D2 receptor, has
bee… … d mechanisms. The net effect of neurotransmitter
inte… … mbic brain region induces "reward" when dopamine
(DA) … neuron at the nucleus accumbens and interacts
with … …or. "The reward cascade" involves the release of
serc… … at the hypothalmus stimulates enkephalin, which
in … … the substania nigra, which in turn fine
tune… … leased at the nucleus accumbens or "reward
site."
It … …der normal conditions in the reward site DA works
to … …ives. In fact, DA has become to be known as the
"ple… … the "antistress molecule." When DA is released
into … …ulates a number a DA receptors (D1-D5) which
resu… … ings of well-being and stress reduction. A
cons… … re suggests that when there is a dysfunction in
the … …, which could be caused by certain genetic
vari… …pecially in the DA system causing a
hypo… …he brain of that person requires a DA fix to
feel
good … multiple drug-seeking behavior. This is so
beca… … heroin, marijuana, nicotine, and glucose all
caus… …onal release of brain DA, which could heal the
abno… … nly after ten years of study we could say with
cont… … of the DAD2 receptor A1 allele have compromised
D2 … ack of D2 receptors causes individuals to have a
high … dictive, impulsive and compulsive behavioral
proj… …ere alcoholism, cocaine, heroin, marijuana and
nico… …geing, pathological gambling, sex addiction,
ADHD … , autism, chronic violence,
pos… …der, schizoid/avoidant cluster, conduct
disorder
and … In order to explain the breakdown of the reward
cas… …ple genes and environmental stimuli
(pl… …ant aberrant behaviors, Blum united this
hyp… …der the rubric of a reward deficiency syndrome.
AB. … …" involves the release of serotonin, which in

tur: stimulates enkephalin, which in turn inhibits
GAB gra, which in turn fine tunes the amount
of : cleus accumbens or "reward. . . compulsive
beh such as severe alcoholism, cocaine, heroin,
mar se, glucose bingeing, pathological gambling, sex
add e's Syndrome, autism, chronic violence,
pos order, schizoid/avoidant cluster, conduct
disorder
and In order to explain the breakdown. . .

L10 ANS COPYRIGHT 2001 ACS DUPLICATE 3
ACCESSIO :464180 CAPLUS
DOCUMENT 111440
TITLE: ds using agents simultaneously acting as
-type glutamate receptor antagonists and GABA-A
ptor agonists for treating tardive dyskinesia and
movement disorders
INVENTOR l, Barry S.
PATENT A hroneuron, LLC, USA
SOURCE: Int. Appl., 106 pp.
: PIXXD2
DOCUMENT nt
LANGUAGE: sh
FAMILY A
PATENT I

PAT	ATE	APPLICATION NO.	DATE
WO	0990722	WO 1999-US144	19990113
WO	0991202		
	JP, MX, NZ		
E	E, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,		
US	0990914	US 1998-6641	19980113
US	0000502	US 1999-224829	19990104
AU	0990802	AU 1999-21041	19990113
EP	0001102	EP 1999-901314	19990113
F,	DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,		
WO	0000525	WO 1999-US27343	19991118
WO	0000720		
	P, MX, NZ		
E	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,		
GE			

PRIORITY IFO.: US 1998-6641 19980113
US 1998-193892 19981118
US 1999-224829 19990104
US 1997-861801 19970522
WO 1999-US144 19990113

AB The reatments for movement disorders, including
tar rdive dystonia, tic disorders, Tourette's
syn and other focal dystonias. The treatments use
age ly act as NMDA-type glutamate receptor
ant e treatments of the invention use agents that
sim DA-type glutamate receptor antagonists and GABA-A
rec rably, these two activities are characteristic
of
a s prosate. Alternatively, sep. agents having
these
act d and administered together. The invention also

pro… a third …at can be used in combination with a treatment
for …ent disc… …hat acts as a non-competitive NMDA-receptor
blo… agent o… …nnel blocker that augments the effect of the
pri… …reatment … …ticularly preferred ion channel blocking agent
is
magn…s . Alter… …, magnesium can be administered alone for
pre… …n and tr… …of movement disorders.
IT Bra… …sease
…s de la … …e syndrome; agents simultaneously acting
… A-type c… …receptor antagonists and **GABA**-A
… …or agoni… …treatment of movement disorders)

L10 ANS… … OF 45 …
ACCESSIO… N …ER: 19… …TOXLIT
DOCUMENT …U… R: CA… …440M
TITLE: Me…
…sing agents simultaneously acting as NMDA-type
gl… …receptor antagonists and GABA-A receptor
agonists
fo… …ng tardive dyskinesia and other movement
di… …
AUTHOR: Fo…
SOURCE: (1… …T Int. Appl. PATENT NO. 9936064 07/22/1999
(S… …uron, LLC).
CO… …XD2.
PUB. COU… UN… …TES
DOCUMENT … : Pa…
FILE SEG… CA…
LANGUAGE: En…
OTHER SO… … CA… …440
ENTRY MO… … 19…
AB The …n… …ntion des… …treatments for movement disorders, including
tard…iv… …dyskinesi… …rdive dystonia, tic disorders, **Tourette**
's …yn… …ome, blep… …m, and other focal dystonias. The treatments use
age… … …hat simul… …y act as NMDA-type glutamate receptor
ant… …sts. Addn… …treatments of the invention use agents that
simu… …eously ac… …A-type glutamate receptor antagonists and
GAB… …eceptor a… …. Preferably, these two activities are
cha… …ristic of … …e agent, e.g. acamprosate. Alternatively, sep.
age… … …aving the… …vities can be combined and administered together.
The …n… …ntion als… …des a third agent that can be used in combination
wit… a …reatment … …ment disorders, that acts as a non-competitive
NMD…-… …eptor blo… …ent or ion channel blocker that augments the
eff… … …f the pri… …atment. A particularly preferred ion channel
blo… … agent is … …um. Alternatively, magnesium can be administered
alon… …f preventi… …treatment of movement disorders.
AB The … …ntion des… …reatments for movement disorders, including
tar… …dyskinesi… …rdive dystonia, tic disorders, **Tourette**
's … … …ome, blep… …m, and other focal dystonias. The treatments use
age…s …hat simult… …y act as NMDA-type glutamate receptor
ant…jc …sts. Addn… …treatments of the invention use agents that
sim… …eously ac… …A-type glutamate receptor antagonists and
GAB… …eceptor a… …. Preferably, these two activities are
cha… …ristic of … …agent, e.g. acamprosate. Alternatively, sep.
age…t …aving the… …ities. . .

L10 ANS… …7 OF 45 …
ACCESSIO… …BER: …1931 USPATFULL
TITLE: …linylamino heterocyclic compounds useful as
…renoceptor agonists
INVENTOR … …, Peter J., Cincinnati, OH, United States

	effrey J., Hamilton, OH, United States
	illiam L., Hamilton, OH, United States
	aniel P., Bloomington, IN, United States
	, Russell James, Fairfield, OH, United States
	aymond T., Pleasant Plain, OH, United States
PATENT A: EE(S):	octer & Gamble Company, Cincinnati, OH, United (U.S. corporation)

	NUMBER	DATE
PATENT I: ATION:		19991012
APPLICAT INFO.:	85085	19961125 (8)
RELATED . INFO.:	ation-in-part of Ser. No. US 1995-478708, filed 1995, now patented, Pat. No. US 5663189 which inuation-in-part of Ser. No. US 1993-86482, 1 Jul 1993, now abandoned	
DOCUMENT E:	Y	
PRIMARY EXAMINER:	n, Jerome D.	
LEGAL RE ENTATIVE:	n, James C.; Roof, Carl J.; Suter, David L.	
NUMBER O AIMS:		
EXEMPLAR AIM:		
LINE COU		

CAS INDE IS AVAILABL IS PATENT.

AB T bject inven ates to compounds having the structure:

l## wherein an integer from 1 to about 3;

(and Y are e pendently selected from O, S and CH.sub.2, with

a st one of X ing O or S;

(is unsubsti traight or branched chain alkanyl or alkanoxy h g from 1 to non-hydrogen atoms; and

(is selecte ydrogen, methyl, cyano, and halo;

p aceutical co ns containing such compounds; and the use of s compounds fo ting or treating of disorders modulated by a -2 adrenocep .

CAS INDE IS AVAILABL IS PATENT.

DETD . . to respi hallenges such as inhaled citric acid. (See,

e Callaway, J ing, "Effects of Inhaled .alpha.2-Adrenoceptor a ABA.sub.B Re gonists on Citric Acid-Induced Cough a idal Volume in Guinea Pigs", European Journal of P acology, Vol .992),. . . The effectiveness of other a -2 agonists nagement of neurologic disorders has been d trated, inc ttention-deficit hyperactive disorder and T te's syndro e.g., Chappell P., M. Riddle, L. S ll, K. Lynch altz, A. Arnsten, J. Leckman & D. Cohen, " facine trea omorbid attention-deficit hyperactivity d ler and Tour ndrome: preliminary clinical e ence", Jour merican Academy of Child and Adolescent P atry, Vol. , pp. 1140-1146), cognitive disorders. . .

L10 ANS 8 OF 45 US

ACCESSIC BER:	92 USPATFULL
TITLE:	azolinylamino)quinoline compounds useful as drenoceptor agonists
INVENTOR	omas Lee, Oxford, OH, United States

'ophie E., Maineville, OH, United States
y.ond T., Pleasant Plain, OH, United States
Russell James, Fairfield, OH, United States
PATENT A: EE(S): ier & Gamble Company, Cincinnati, OH, United
.S. corporation)

ER DATE
PATENT I: ATION: 0 19990629
APPLICAT INFO.: 5?118 19961125 (8)
RELATED N. INFO.: n-in-part of Ser. No. US 1995-496796, filed
1995, now patented, Pat. No. US 5716966

DOCUMENT :
PRIMARY E INER: eh
LEGAL RE: ENTATIVE: , James C.; Graff, Milton B.; Suter, David L.
NUMBER O: AIMS:
EXEMPLAR AIM:
LINE COU:
CAS INDE IS AVAILABL C PATENT.
AB T: Invention in volves the use of compounds having the
f: wing structu #1## wherein: (a) R is unsubstituted C.sub.1
- .3 alkanyl l; and

(is selecte drogen; unsubstituted C.sub.1 -C.sub.3
alkanyl
o: enyl; unsub C.sub.1 -C.sub.3 alkylthio or alkoxy;
hydroxy;
t: ; cyano; and

f: eventing or ; of disorders modulated by alpha-2
a ceptors.

T: bject inven involves novel compounds and compositions.

CAS INDE: IS AVAILABL .3 PATENT.
DETD . . to respi allenges such as inhaled citric acid. (See,
e. Callaway, J ng, "Effects of Inhaled .alpha.2-Adrenoceptor
a: ABA.sub.B Re onists on Citric Acid-induced Cough
a: dal Volume n Guinea Pigs", European Journal of
P. cology, Vol 92),. . . The effectiveness of other
a: -2 agonists nagement of neurologic disorders has been
d trated, inc ttention-deficit hyperactive disorder and
T: te's syndro e.g., Chappell P., M. Riddle, L.
S 1, K. Lynch litz, A. Arnsten, J. Leckman & D. Cohen,
" facine trea omorbid attention-deficit hyperactivity
d ler and Tour drome: preliminary clinical
e ence", Jour erican Academy of Child and Adolescent
P atry, Vol. , pp. 1140-1146), cognitive disorders. . .

L10 ANS 9 OF 45 US
ACCESSIO BER: USPATFULL
TITLE: inylamino heterocyclic compounds useful as
enoceptor agonists

INVENTOR er J., Cincinnati, OH, United States
ey J., Hamilton, OH, United States
lliam L., Hamilton, OH, United States
niel P., Bloomington, OH, United States
Russell James, Fairfield, OH, United States
ymond T., Pleasant Plain, OH, United States

PATENT A[illegible]EE(S): [illegible]er & Gamble Company, Cincinnati, OH, United [illegible].S. corporation)

	[illegible]ER	DATE
PATENT I[illegible] [illegible]ATION:	4 [illegible]2	19990622
APPLICAT[illegible] [illegible]NFO.:	8-[illegible]59698	19980924 (9)
RELATED [illegible]. INFO.:	[illegible]f Ser. No. US 1996-756085, filed on 25 Nov [illegible]h is a continuation-in-part of Ser. No. US [illegible]8, filed on 7 Jun 1995, now patented, Pat. [illegible]3189	
DOCUMENT [illegible]:		
PRIMARY E[illegible] [illegible]NER:	[illegible]	Jerome D.
LEGAL RE[illegible] [illegible]NTATIVE:	[illegible]	[illegible], James C.; Roof, Carl J.; Graff, Milton B.
NUMBER O[illegible] [illegible]IMS:		
EXEMPLAR[illegible] [illegible]IM:		
LINE COU[illegible]		

CAS INDE[illegible] [illegible] IS AVAILABL[illegible] [illegible]S PATENT.

AB Th[illegible] [illegible]bject inven[illegible] [illegible]es to compounds having the structure:

[illegible]## [illegible]## wherein [illegible]n integer from 1 to about 3;

([illegible] and Y are e[illegible] cl[illegible] [illegible]endently selected from O, S and CH.sub.2, with

a[illegible] [illegible]st one of X [illegible]eing O or S;

([illegible] is unsubsti[illegible] [illegible]straight or branched chain alkanyl or alkanoxy ha[illegible] [illegible] from 1 to [illegible]c [illegible]n-hydrogen atoms; and

([illegible] is selecte[illegible] [illegible]ydrogen, methyl, cyano, and halo;

ph[illegible] [illegible]ceutical co[illegible] [illegible]s containing such compounds; and the use of su[illegible] [illegible]ompounds fo[illegible] p[illegible] [illegible]ing or treating of disorders modulated by a[illegible] [illegible]-2 adrenocep[illegible]or

CAS INDE[illegible] [illegible]IS AVAILABL[illegible] [illegible]T IS PATENT.

DETD [illegible]. [illegible]. to respi[illegible] [illegible]allenges such as inhaled citric acid. (See, e.[illegible] [illegible]Callaway, [illegible] [illegible]g, "Effects of Inhaled .alpha.2-Adrenoceptor ar[illegible] [illegible].BA.sub.B Re[illegible] [illegible]nists on Citric Acid-Induced Cough ar[illegible] [illegible]dal Volume [illegible]. Guinea Pigs", European Journal of Ph[illegible] [illegible]cology, Vol [illegible]2),. . . The effectiveness of other a[illegible] [illegible]2 agonists n[illegible] [illegible]nagement of neurologic disorders has been d[illegible] [illegible]trated, inc[illegible] [illegible]ttention-deficit hyperactive disorder and To[illegible] [illegible]tte's syndro[illegible] [illegible]e e.g., Chappell P., M. Riddle, L. S[illegible] [illegible]., K. Lynch [illegible] [illegible]ltz, A. Arnsten, J. Leckman & D. Cohen, "[illegible] [illegible]acine trea[illegible] [illegible]omorbid attention-deficit hyperactivity d[illegible] [illegible]er and Tour[illegible] [illegible]drome: preliminary clinical e[illegible] [illegible]ence", Jour[illegible] [illegible]rican Academy of Child and Adolescent Ps[illegible] [illegible]atry, Vol. [illegible] [illegible] pp. 1140-1146), cognitive disorders. . .

L10 ANS[illegible] [illegible]) OF 45 US A[illegible]

ACCESSIO[illegible] [illegible]ER: [illegible] [illegible]18 USPATFULL

TITLE: [illegible] [illegible]azolinylamino) quinolines useful as alpha-2 [illegible] [illegible]tor agonists

INVENTOR [illegible] [illegible]as Lee, Oxford, OH, United States
[illegible] [illegible]ter J., Cincinnati, OH, United States
[illegible] [illegible]rey J., Hamilton, OH, United States
[illegible] [illegible]mond T., Pleasant Plain, OH, United States
[illegible] [illegible]ussell James, Fairfield, OH, United States
[illegible] [illegible]llen E., West Chester, OH, United States
[illegible] [illegible]ophie E., Maineville, OH, United States

PATENT A[illegible]E(S): [illegible] & Gamble Company, Cincinnati, OH, United [illegible] corporation)

	NUMBER	DATE
PATENT IN[illegible]TION:	[illegible]7	19980908
APPLICATI[illegible]NFO.:	[illegible]55936	19961125 (8)
RELATED [illegible] INFO.:	[illegible]ion-in-part of Ser. No. US 1995-496704, filed [illegible] 1995, now patented, Pat. No. US 5739148	

DOCUMENT [illegible]
PRIMARY E[illegible]ER: [illegible]obert W.
ASSISTANT [illegible]INER: [illegible]benezer O.
LEGAL REP[illegible]TATIVE: [illegible]hard A.; Graff, Milton B.; Suter, David L.
NUMBER OF [illegible]IMS:
EXEMPLARY [illegible]M:
LINE COUN[illegible]
CAS INDEX[illegible]S AVAILABL[illegible] PATENT.
AB The [illegible]bject inve[illegible]ates to compounds having the structure: [illegible] # as defi[illegible]e claims, and to pharmaceutical compositions co[illegible]ing such [illegible]and the use of such compounds for preventing or [illegible]ting of d[illegible]odulated by alpha-2 adrenoceptors.

CAS INDEXI[illegible]S AVAILABL[illegible]G PATENT.
DETD [illegible] to respi[illegible]allenges such as inhaled citric acid. (See, e.[illegible]allaway, [illegible]ng, "Effects of Inhaled .alpha.2-Adrenoceptor a[illegible]A.sub.B R[illegible]nists on Citric Acid-Induced Cough a[illegible]al Volume[illegible]n Guinea Pigs", European Journal of Pl[illegible]ology, Vo[illegible]9[illegible]. . . The effectiveness of other al[illegible] agonists [illegible]nagement of neurologic disorders has been d[illegible]rated, in[illegible]ttention-deficit hyperactive disorder and To[illegible]e's syndr[illegible]e.g., Chappell P., M. Riddle, L. Sca[illegible], K. Lync[illegible]litz, A. Arnsten, J. Leckman & D. Cohen, "C[illegible]cine trea[illegible]omorbid attention-deficit hyperactivity d[illegible]r and Tou[illegible]rome: preliminary clinical e[illegible]nce", Jo[illegible]rican Academy of Child and Adolescent P[illegible]ry, Vol. [illegible], pp. 1140-1146), cognitive disorders. . .

L10 ANS[illegible] OF 45 U[illegible]
ACCESSIO[illegible]ER: [illegible] USPATFULL
TITLE: [illegible]inine in treating psychiatric disorders
INVENTOR[illegible] [illegible]d, Minneapolis, MN, United States
PATENT A[illegible]E(S): [illegible]oration, Minnetonka, MN, United States (U.S.

	NUMBER	DATE
PATENT I[illegible]TION:	[illegible]	19980707
APPLICAT[illegible]FO.:	[illegible]3363	19960730 (8)

DOCUMENT[illegible]
PRIMARY [illegible]ER: [illegible]Willis G.
LEGAL RE[illegible]ATIVE: [illegible]es V.
NUMBER O[illegible]S:
EXEMPLAR[illegible]:
LINE COU[illegible]
CAS INDE[illegible]S AVAILA[illegible] PATENT.
AB A [illegible]ceutica[illegible]n is provided that is useful in treating c[illegible]e-compu[illegible]s, Tourette's Syndrome and schizophrenia c[illegible]ing an a[illegible]inine or a pharmaceutically acceptable salt

t… which … effective to reduce or alleviate at least one
c… ymptom… … s Syndrome, obsessive-compulsive disorder,
c… ophren… … or other mammal.

CAS INDE… … AVAIL… … PATENT.
DETD … has a… … inhibitory effect of nicotine with respect
t… an enzy… … converts glutamate into gammaaminobutyric acid
(
G… he rat… … ic acid to **GABA**
(… inobut… … the brain plays a crucial role in brain
a… … Gluta… … citatory transmitter. **GABA** is an
i… …y tra… … Furthermore, the concentration of glutamate and
G… … highe… … than they are in the rest of the
b… …e effe… … otinine to inhibit. . . behavior) which
m… … devel… … ny years. This sheds light on the
e… …eness … … in treating obsessive-compulsive disorder,
T… …'s Syn… … schizophrenia through its ability to
i… the ac… … D so as to make the patient feel better,. .
.

L10 ANS… …F 45 … …T 2001 DERWENT INFORMATION LTD
ACCESSIO… …R: … …6] WPIDS
DOC. NO. …
TITLE: … GABA-uptake related disorders - used for
… headaches, dementia, alcohol withdrawal
… spasticity, growth disturbances, tardive
… or alcohol abuse.

DERWENT …
PATENT A… …(S): … …O-NORDISK AS
COUNTRY …
PATENT I… …ION:

PAT…	KIND	…TE	LA	PG
DK	A	…96)*		1

APPLICAT… …AILS:

PAT…	KIND	APPLICATION	DATE
DK	A	DK 1998-727	19980528

PRIORITY … INFO: … 19980528
AN 199… …1 [46] …
AB DK … …27 A U… 1 …8
Met… … the t… … GABA-uptake related disorders such
as … headac… … ia, alcohol withdrawal symptoms, spasticity,
gro… …urban… … …yskinesia, alcohol abuse, **stuttering**
, h… …hes, H… … hocrea, Gilles di le **Tourettes**
syn… …incont… … …etic neuropathy and postherpetic neuralgia.
Dwg…
AB DK … …27 … … 8
Met… … the t… … GABA-uptake related disorders such
as … …eada… … …ia, alcohol withdrawal symptoms, spasticity,
gro… …rban… … …yskinesia, alcohol abuse, **stuttering**
, h… …es, H… … …rea, Gilles di le **Tourettes**
syn… …ncont… … …c neuropathy and postherpetic neuralgia.
Dwg…

L10 ANS ... 45 ... YRIGHT 2001 BIOSIS DUPLICATE 4
ACCESSIC ... 1 ... ICSIS
DOCUMENT ... 311
TITLE: ... to glutamate decarboxylase in a patient with ... llar degeneration and Sjogren syndrome.
AUTHOR(S ... ; Harada, Toshihide; Kamei, Hidekazu;
Nakamura
CORPORAT ... Internal Med., Hiroshima Univ. Sch. Med., 1-2-3 ... -ku, Hiroshima 734 Japan
SOURCE: ... e (Tokyo), (Feb., 1998) Vol. 50, No. 2, pp. ... 59.
DOCUMENT
LANGUAGE
SUMMARY ... English

AB We ... 52- ... n with Sjogren syndrome from the age of 46, dev ... erebe ... , autonomic dysfunction and **dysarthria** at ... had n ... tory, and all known causes of cerebellar dis ... re exc ... of the patient contained autoantibodies dir ... against ... d decarboxylase(GAD) which was an enzyme inv ... n the ... s of **GABA**. She also had aut ... dies t ... ecific with Sjogren syndrome(SS-A, anti-nuc ... ant ... nti- ... b ... y changed into negative after high dose int ... and ... steroid therapy, but symptoms did not improve. Wes ... me ... abnormal bands to human neuroblastoma cell lin ... 13, 4 ... ed relatively specific to nervous tissue. In thi ... erebe ... n and atrophy were caused by autoimmune pat ... inc ... llar GABAergic system and central nerve ce

AB We ... 72- ... n with Sjogren syndrome from the age of 46, dev ... ebe ... , autonomic dysfunction and **dysarthria** at ... had n ... tory, and all known causes of cerebellar dis ... exc ... f the patient contained autoantibodies dir ... gains ... d decarboxylase(GAD) which was an enzyme inv ... n the ... of **GABA**. She also had aut ... les ... ecific with Sjogren syndrome(SS-A, anti-nu ... an ... nti- ... changed into negative after high dose.

L10 AN ... RIGHT 2001 INIST-CNRS. ALL RIGHTS RESERVED.
ACCESSIO ... 25 PASCAL

TITLE (I ... n of a Tourette-like syndrome with ofloxac
AUTHOR: ... J.; REAGAN D. R.; RODRIGUEZ DE BITTNER M. ... MARTINEAU P. (trad.)
CORPORAT ... ssee State univ., James H Quillen coll. ... p. internal medicine, Murfreesboro TN ... ted States
SOURCE: ... of pharmacotherapy, (1996), 30(2), 138-141,
... -0280
DOCUMEN ... ase report, clinical case); Translation

BIBLIOG
COUNTRY:
LANGUAG
SUMMARY
AVAILAB
AN 1
CP C
ABFR O
o
a
T
a
p
l'
e
l'
d
c
a
l'
L'
c
d
l
G
r
a
p
c
p
l'
a
a
s

a
r
p
s
ABFR.
d'

au
s
r

fut
o
c
a
l'
L'
c
f
p
d

cas
s'
l'
l
:

French
5, 354000052895180050
PY
CT-CNRS. All rights reserved.
tion entre l'emploi de la fluoroquinolone
et le developpement d'une encephalopathie
ristiques similaires au syndrome de La
yndrome insolite, relie dans le temps
t avec l'ofloxacine, fut observe chez un
me disparut completement apres
es caracteristiques les plus remarquables
coprolalie ; on a egalement observe de
des automatismes orofaciaux et des membres,
l'amnesie concernant l'episode pendant la
on clinique avait plusieurs points en commun
tte et possiblement avec de
e originant du lobe frontal.
examens neuroradiologique, et du liquide
SION : Les effets neurotoxiques documentes
l'insomnie, les convulsions, le delire, et
par les proprietes antagonistes du
ments. Il s'agit ici du premier
t au syndrome de La **Tourette**,
quinolone, suggerant une interaction
neurotransmetteurs dopaminergiques
ge de medicaments qui, comme l'ofloxacine,
ation dans le systeme nerveux central,
ale associee aux maladies ou a l'age
de substances telles la theophylline et les
ens, et possiblement l'augmentation de la
, classent la personne agee dans un groupe

icite aux quinolones. Les ajustements
des effets indesirables au niveau du
primordiaux.
line chez un homme age et le developpement
sentant des caracteristiques similaires

DU CAS Un syndrome insolite,
ation d'un traitement avec l'ofloxacine,

l'amnesie concernant l'episode pendant la
on clinique avait plusieurs points en commun
tte et possiblement avec de
originant du lobe frontal.
examens neuroradiologique, et du liquide
neurotoxiques documentes des
l'insomnie, les convulsions, le delire, et la
es proprietes antagonistes du **GABA**
is. Il s'agit ici du premier rapport d'un

de L **Tourette**, associe a
, suggerant une interaction possible avec
urs dopaminergiques centraux. CONCLUSIONS

ACCESSIC 16 [2] WPIDS
DOC. NO. 75
TITLE: ons of sugars and amino acids, opt with other for t eatment of, e.g., Alzheimer's disease, n, hair loss, cancers, hypertension, etc.

DERWENT
INVENTOR T; NAITO, A
PATENT A NAITO A T; (NAIT-I) NAITO A
COUNTRY
PATENT I

PAT	WEEK	LA	PG
EP	(1995 3)*	EN	13
	R GB GR IE IT LI LU MC NL PT SE		
CA	(1997)#		

APPLICAT

PAT	APPLICATION	DATE
EP	EP 1993-308852	19931105
CA	CA 1993-2103399	19931118

PRIORITY 08852 19931105; CA 1993-2103399

AN 199
AB EP 619
Co one or more pure sugars selected from meso
ery alact se, D(+)lactose, D(+)xylose, dulcitol,
myo , D(-)mannitol, sorbitol, D(+)glucose,
D(+, se, c llobiose, D(+)maltose, D(+)raffinose,
L(+, e, D(-)ribose, adonitol, D(+)arabitol,
L(- L(-)f cose, D(-)lyxose, L(+)lyxose, L(-)lyxose,
D(+ amine nd D galactosamine; and (b) one or more
ami glutamine, lysine, arginine, asparagine,
as glutamic acid, glycine, histidine, leucine,
met nylalanine, serine, threonine, tryptophan,
ty ne.
s are capable of passing through the
blood-br
bar f (i) restoring impeded neuro-transmitter
fun g other materials (e.g. beta-carotene,
xan cin, somastatin, vasopressin, endorphin,
enk ftine, GABA, dynorphin, L-tryptophan,
ch oxin , niacin, L-arginine, hydroxyproline, NGF,
met sium, phosphorus, chlorine, sodium, vitamins A,
B, m phosphate, selenium, linolenic acids, etc.)
th rrier, or (iii) otherwise facilitating the
uti materials in the chemical processes of the
bod t. together with these other materials) may be
use dependence, drunkeness, Alzheimer's disease,
Hu ophrenia, loss of hair, depression, insomnia,
ch , heart muscle disorders, stress, headache,
st bulimia anorexia, panic disorders,
an muscular dystrophy, cerebral palsy, Parkinson's
di , cancers, acne, psoriasis, eczema,
lu sclerosis, AIDS, chronic fatigue, ageing
sy m also be used in athletic drinks.

Dwc

AB .

of ... ansmitter function, (ii) transporting
oth... ...ene, xanthophyll, lecithin, calcium,
son... ...in, enkephalin, acetyl-L-carnitine,
GAB... ...holine, thiamine, pyridoxine,
nia... ...oxyprolone, NGF, methionine, cystine, potassium,
pho... ...dium, vitamins A, B, C, K,. . . dependence,
dru... ...disease, Huntington's disease, schizophrenia,
loss
of ... ...hronic pain, osteoporosis, heart muscle
dis... ..., **stuttering**, poor memory, bulimia,
and... ...s, anxiety, hyperactivity, muscular dystrophy,
cer... ...on's disease, hypertension, PMS, shock, cancers,
ac...

L10 AN... ...COPYRIGHT 2001 BIOSIS DUPLICATE 5
ACCESSIO... ...OF BIOSIS
DOCUMEN... ...96008
TITLE: ...some related psychopharmacological
...ourette's syndrome: An update.
AUTHOR(S)... ...Chokka, P. R.; Bornstein, R. A.
CORPORA... ...Psychopharm. Res. Unit, Dep. Psychiatry, Univ. Alberta,
..., AB T6G 2B7 Canada
SOURCE: ...of Psychopharmacology, (1995) Vol. 9, No. 3, pp.
...- 811.

DOCUMEN...
LANGUAG...
AB Neu... ...ions of **Tourette**'s syndrome (TS) suggest
th... ...s disorder may be the result of an imbalance
among
se... ...and/or neuromodulator systems. Neurochemicals
whi... ...including: catecholamines; acetylcholine;
try... ...olites; the amino acids gamma-aminobutyric acid (
GAB... ...amine and p-tyrosine; trace amines;
opi... ...and androgenic hormones. A suitable animal
mo... ...to advance our understanding of this disorder,
and... ...ecent developments in this regard.
AB Neu... ...ions of **Tourette**'s syndrome (TS) suggest
th... ...is disorder may be the result of an imbalance
among
se... ...and/or neuromodulator systems. Neurochemicals
whi... ...including: catecholamines; acetylcholine;
tr... ...olites; the amino acids gamma-aminobutyric acid (
GA... ...amine and p-tyrosine; trace amines;
op... ...androgenic hormones. A suitable animal
mo...

L10 AN... ...DUPLICATE 6
ACCESSI... ...MEDLINE
DOCUMEN...
TITLE: ...on of dysarthria in multiple sclerosis by
treatme...
...magnetic fields.
AUTHOR:
CORPORA... ...Research Laboratories, Danbury, CT
...A.
SOURCE: ...IONAL JOURNAL OF NEUROSCIENCE, (1995 Nov) 83 (1-2)

PUB. CO[illegible] ...od. : [illegible] . ISSN: 0020-7454.
[illegible] United Kingdom
[illegible] Arti[illegible] (JOURNAL ARTICLE)
LANGUAG[illegible]
FILE SE[illegible] Jou[illegible]
ENTRY M[illegible]
ENTRY W[illegible]

AB It [illegible] or more of patients diagnosed with multiple scl[illegible] speech impairment (**dysarthria**) which in so[illegible] sabling. Currently there is no effective medic[illegible] he [illegible]hria of MS which occurs as a res[illegible] e ce[illegible] lum and its outflow tracts. It was rep[illegible] extra[illegible]ial application of brief AC pulsed el[illegible] (EMFs) [illegible] the picotesla (pT) range intensity pr[illegible] h MS sustained improvement in motor functions in[illegible] [illegible]tology. This communication concerns two MS patie[illegible] progressive course who exhibited severe **dys**[illegible] during the initial treatment wi[illegible] [illegible]ch [illegible] solved completely 3-4 weeks later. Since ap[illegible] been [illegible] wn to alter: (a) the resting membrane po[illegible] neur[illegible] smitter release through an effect in[illegible] transm[illegible] ne calcium flux; and (b) the secretion of pi[illegible] in turn influences the synthesis and release of se[illegible] [illegible]ma-amino **butyric** **ac**[illegible] [illegible], it is suggested that the immed[illegible] dysarthria occurred as a result of ch[illegible] [illegible]mitter functions particularly 5-HT and **GA**[illegible] [illegible]myel[illegible]ion.

AB It [illegible] at [illegible] more of patients diagnosed with multiple scl[illegible] speech impairment (**dysarthria**) which in so[illegible] sabling. Currently there is no effective me[illegible] [illegible]hria of MS which occurs as a re[illegible] [illegible]llum and its outflow tracts. It was re[illegible] motor functions including cerebellar sy[illegible] [illegible]on concerns two MS patients with a chronic pr[illegible] severe **dysarthria** which im[illegible] the [illegible]ial treatment with pulsed EMFs and which resol[illegible] wee[illegible] later. Since application of. . . flux; an[illegible] (b) [illegible] melatonin which in turn influences the sy[illegible]the[illegible] in (5-HT) and **gamma**-**am**[illegible]no [illegible] ce[illegible] eb[illegible] the immediate improvement of the dysar[illegible] of changes in cerebellar neuro[illegible] [illegible]cularly 5-HT and **GABA** rather th[illegible]n [illegible]

L10 A[illegible] C[illegible]HT 2001 DERWENT INFORMATION LTD
ACCESS[illegible] P T S
TITLE: [illegible]oversy of CNS Stimulants in Gilles de la [illegible]
AUTHOR: [illegible] F[illegible]n V
LOCATI[illegible]: [illegible]dom
SOURCE: [illegible] (15, No. 5, 408-25, 1992) 2 Tab. 154 Ref.
[illegible] ISSN: 0722-5091
AVAIL. F[illegible] [illegible] Psychiatry, Middlesex Hospital, London W1N [illegible]
LANGUAGE:
DOCUMENT TY[illegible]

FIELD AVAIL
FILE SEGMEN
AN 1993-
AB The c stimulants e.g. dextroamphetamine
(dexa ine, L-amphetamine, or methylphenidate in the
treat a Tourette's syndrome (GTS)
parti , is viewed considering the relationship
betwe n defi it-hyperactivity disorder (ADHD) and the
contr eatment with stimulants. Neurobiochemical systems
consi (DA , orepinephrine (noradrenaline), 5-HT, ACh,
GABA of choice for GTS are DA antagonists and
clonic ADHD are stimulants. Stimulants may cause
tics, eighed up against the benefits of their use.
Side-e ol (D antagonist) are depression/dysphoria,
sedati un in . CL may be the drug of choice for a
patie A HD.
ABEX High stimulants, e.g. pemoline, L-amphetamine and
dextr to treat ADHD can provoke or exacerbate tics or
CTS in wi out these preexisting symptoms. Tics are
less
likely by stimulants in patients treated with
halope re is evidence that stimulants and
butyrop mply antagonistic to each other but have
overlap effects on tics and side-effects. Levodopa
given t ients can result in involuntary vocalization
and
apomorph reate nd decrease GTS. Obsessive-convulsive
componer d th LSD and psilocin. CL is effective for
both ti ms bu if hyperactivity is a significant
problem, w or without butyrophenones/benzamides may be
tried i doses and with relevant monitoring. The
neurobi erbation of tics/GTS is based on the release of
dopamin e ine from pre-synaptic nerve terminals.
Abnormal nsmitters such as DA, noradrenaline, 5-HT, ACh,
GABA and (e.g. dynorphin) are noted in GTS. Other drugs
used in include sulpiride, fluphenazine, naltrexone,
clomipra , methylphenidate, clonazepam, nifedipine,
verapami , trifluoperazine, progabide and physostigmine.
Other t include amitriptyline, desipramine,
imipramine,
bupropi , chlorphenhydramine, chlorpromazine, propranolol and
carbamaz , F .E.).
AB The cont stimulants e.g. dextroamphetamine
(dexamph line, L-amphetamine, or methylphenidate in the
treatmen a Tourette's syndrome (GTS)
particul iewed considering the relationship
between it-hyperactivity disorder (ADHD) and the
contrain nt with stimulants. Neurobiochemical systems
consider , orepinephrine (noradrenaline), 5-HT, ACh,
GABA and f choice for GTS are DA antagonists and
clonidin A HD are stimulants. Stimulants may. . .

L10 ANSWER 2 COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMB M S
TITLE: -Lactam Antibiotics: Predisposing
esis.
AUTHOR: ars O; Norrby S R
LOCATION: , Sweden
SOURCE: ourner. (27, No. 4, 405-25, 1991) 3 Tab. 169
Ref.

ISSN: 0305-7453
AVAIL. OF DOC.: ... cology, University of Umea, S-90185 Umea,

LANGUAGE:
DOCUMENT TYPE:
FIELD AVAIL.:
FILE SEGMENT:
AN 1991-27570
AB Neurotoxic ... togenic activity, of beta-lactams e.g. benzylpeni ... (CF), ampicillin (AP), amoxicillin (AM), oxacillin ... (CC), nafcillin (NC), carbenicillin (CB), ticarcilli ... n (PP), cefaloridine (CR), cefalotin (CT), cefonicid ...), cefmetazole (CZ), cefacetrile (CA), cefotaxime ... (CD), cefuroxime (CU) and latamoxef (LM), and imipen ... penem and FCE-22101 are reviewed. Other drugs ment ... fentanyl, meperidine, ketamine, halothane, propanidid ... caine, theophylline, aminophylline, amphetamin ... taline, phenyl-propanolamine, physostigmine, isoniazid, ... idixic acid, chlorambucil, misonidazole and cyclospori...
ABEX Neurotoxic ... beta-lactam antibiotics occur frequently and epilep ... observed after very high systemic doses. Highest pc ... with BP, CF and imipenem/cilastin (also meropenem ... l or more of seizures, aggravation of myasthenia ... ions, confusion, nystagmus, encephalopathy, myoclonus, ... d reaction, **dysarthria**, delerium, ... ting, rapid eye movements, tachycardia, headache, ... s and neuromuscular excitability are recorded f ..., CB, TC, PP, CR, CT, CF, CN, CL, CZ, CA, CX, CD, CU ... factors include concurrent or prior BP, warfarin, ... in, tobramycin, cefoperazone or amikacin. Drugs kno... lower seizure thresholds are alcohol, fentanyl, ... e, pentazocine, propoxiphene, halothane, enflurane, ... caine, lidocaine, procaine, etidocaine, theophylli... amphetamine, ephedrine, terbutaline, phenylprop... phates, physostigmine, isoniazid, metronidaz... , quinolones, chlorambucil, misonidazole and cyclospori... rotoxicity in rats and increased sensitivit... thiobarbital and influence of probenecid are discus... dicloxacillin, phenethicillin, /3H/flunit... etrazole, ceftezole, cefamandol... ocillin are mentioned. (E4/AK)
ABEX. . . and ... more of seizures, aggravation of myasthenia ... ns, confusion, nystagmus, encephalopathy, myoclonus, ... d reaction, **dysarthria**, delerium, ... ng, rapid eye movements, tachycardia, headache, ... s and neuromuscular excitability are recorded f ... . . in rats and increased sensitivity to hexobarbit... d influence of probenecid are discussed. In pathoge... n, phenethicillin, /3H/flunitrazepam, **GABA**, pent... e, cefamandole, ceftizoxime and azlocillin... /K)

L10 ANSWER 30 ... 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: [illegible] M S
TITLE: [illegible]-Effects of Various Antibacterial

AUTHOR: [illegible]
LOCATION: [illegible]ny, West
SOURCE: [illegible]upp 1. 1, S29-S32, 1991) 87 Ref.
ISSN: 0300-8126
AVAIL. OF DOC.: [illegible]linik, Universitaet Goettingen,
[illegible]sse 5, W-3400 Goettingen, Germany.

LANGUAGE:
DOCUMENT TYPE:
FIELD AVAIL.:
FILE SEGMENT:
AN 1991-12408
AB Side-effec[illegible] on the CNS are reviewed with reference to quinolone [illegible]icillins, cephalosporins, erythromyc[illegible], metronidazole, isoniazid, sulfonamides and tetracycli[illegible].
ABEX CNS-effect[illegible] include fits, headaches, vertigo, visual disturbanc[illegible]ects, sleeping problems, psychoses, lassitude and confus[illegible] similar to those of nalidixic acid, rosoxacin and pipede[illegible]acin, ofloxacin and ciprofloxacin can act through in[illegible]etabolism of theophylline, caffeine and paraxanthi[illegible] A-receptors, through pyschoanal[illegible]ated to the structural similarities to amfonelic [illegible]tamine-like effects. Quinolone-psychoses can be treated [illegible]e, and benzodiazepines can be used in cases of convuls[illegible]icillins (amoxicillin, carbenicillin, ticarcilli[illegible]benzylpenicillin, oxacillin, cloxacillin, dicloxacill[illegible]d-symptoms including psychoses with agitation, disorienta[illegible]tinations and sleeping problems. Benzathine- and procai[illegible] cause a psychiatric symptom-complex (procaine-[illegible]caine also has CNS toxicity. I.v. cephalospo[illegible]llucinations, convulsions, disorientation and restlessne[illegible] cause anxiety and optical hallucinations. Gentamicin[illegible]ses and encephalopathy in adults, and kanamycin c[illegible]s and visual disturbances. Metronidazole can cause ence[illegible]lsions, ataxia, **dysarthria** and cerebellar [illegible]azi[illegible] can cause vertigo, excitation, cerebral organic ps[illegible]convulsions and hyper-reflexia. Sulfanilam[illegible]de can cause sight disturbances, vertigo, depressio[illegible]psychoses. (S67/LJ) (Zentralnervoese Nebenwirku[illegible]antibakterieller Substanzen.)
ABEX. . . and [illegible]floxacin, ofloxacin and ciprofloxacin can act through [illegible]50-metabolism of theophylline, caffeine and paraxanthi[illegible] A-receptors, through pyschoanal[illegible]ated to the structural similarities to amfonelic [illegible]tamine-like effects. Quinolone-psychoses can be treated [illegible]ine psychoses and encephalopathy in adults, and kanam[illegible]s and visual disturbances. Metronidazole can cause [illegible]sions, ataxia, **dysarthria** and cerebellar [illegible] can cause vertigo, excitation, cerebral organic ps[illegible]nvulsions and hyper-reflexia. Sulfanilam[illegible]e can cause. . .

L10 ANSWER 31 ...T 2001 DERWENT INFORMATION LTD
ACCESSION NUMBE... T P S
TITLE: ...fferent Vigabatrin Treatment Regimens on CSF ... Seizure Control in Epileptic Patients.
AUTHOR: ...ersson L I; Schechter P J; Haegele K D; ...berg J
CORPORATE SOURC...
LOCATION: ...n; Strasbourg, France
SOURCE: ...col. (27, Suppl. 1, 79S-85S, 1989) 3 Fig. 3 Tab. 21 R...
ISSN: 0306-5251
AVAIL. OF DOC.: ...rology, University of Goteborg, Goteborg, (...s).
LANGUAGE:
DOCUMENT TYPE:
FIELD AVAIL.:
FILE SEGMENT:
AN 1989-3010...
AB P.o. viga... ...in a decrease in seizure frequency when administe... ...ith drug-resistant complex partial epilepsy. ... progressively decreased with decreasing dosing int... ...fects included **stutter**, drowsiness, lossof co... ...sion and irritability and increased vigor. VB resulted ... ...ases in CSF levels of free and total **GABA** and ... ...CSF concentrations of homovanillic acid (HVA... ...icantly after a single dose of VB but returned to pretrea... ...ubsequent dosing schedules. In contrast, 5-HIAA co... ...increased with the single dose but were significa... ...wing alternate day and daily VB administr... ...drugs included phenytoin (PH), carbamazepine (CB) and ...
ABEX 11 Patien... ...r, mean 32.4) with drug-resistant epilepsy with over... ...admitted to the study. 2 Patients were being trea... ...5 with CB alone, 2 with both and 2 with PB and CB. ... ...p.o. VB, 50 mg/kg as add-on therapy. The drug was ... ...morning dose. The patients then received 50 mg/kg eve... ...followed by 50 mg/kg every other day for a further 2 ... ...he dosage interval was reduced to daily administr... ...th. CSF total and free **GABA** and HVA level... ...increased, compared with pretreatment values, ...dose of VB and remained elevated at subsequen... ...increases were dose-dependent. VB concentra... ...ater with every 3rd day dosing and every other day ... ...le dose. CSF concentrations of 5-HIAA after si... ...eased over pre-treatment levels. A signifi... ...d for values observed after alternate day and daily ... ...ed to pre-treatment concentrations. CSF levels of ... ...llowing single VB dosage. 1 Patient had to withd... ...ness, loss of concentration and development of a **stu**... ...developed depressive symptoms and irri... ...reported increased vigor. 1 Reported mild drowsine... ...3rd day 4/11 patients had a decrease in seizure ... ...0% while 1 patient increased frequency. With alt... ...had a greater than 50% decrease in frequenc... ...requency in 8/10 cases including

eliminat[illegible] in 2. (Y112/SEB)
AB. . . adm[illegible] with drug-resistant complex partial
epilepsy. [illegible] gressively decreased with decreasing
dosing i[illegible] s included **stutter**, drowsiness,
lossof c[illegible] and irritability and increased vigor.
VB
resulted [illegible]s in CSF levels of free and total
GABA and [illegible] CSF concentrations of homovanillic
acid (HV[illegible] [illegible]ly after a single dose of VB but
returned
to. . .
ABEX. . . a[illegible], the dosage interval was reduced to
daily ad[illegible] mth. CSF total and free **GABA**
and HVA [illegible]y increased, compared with pretreatment
values, [illegible]e of VB and remained. . . increased
followin[illegible] [illegible]atient had to withdraw because of
drowsine[illegible]n and development of a **stutter**.
Another [illegible]sive symptoms and irritability. 2
Patients [illegible]r. 1 Reported mild drowsiness. With VB
given ev[illegible]

L10 ANSWER 3 [illegible] 2001 DERWENT INFORMATION LTD
ACCESSION NUME[illegible] T B V
TITLE: [illegible]cidemia Type I: Effect of Riboflavin and
[illegible]

AUTHOR: [illegible] Goodman S I; Batshaw M L
LOCATION: [illegible] Durham, Denver, Colorado, United States
SOURCE: [illegible] 1, 62-65, 1988) 1 Fig. 1 Tab. 15 Ref.
[illegible] ISSN: 0022-3476
AVAIL. OF DOC.: [illegible]tute, 707 N. Broadway, Baltimore, MD
[illegible]

LANGUAGE:
DOCUMENT TYPE:
FIELD AVAIL.: [illegible]
FILE SEGMENT: [illegible]
AN 1988-104[illegible]
AB A 5-yr-o[illegible] glutaric acidemia associated with
progress[illegible] [illegible]sy and basal ganglia degeneration and
who resp[illegible] [illegible] (RF) and l-carnitine (CT) with
evidenced
of bioch[illegible] [illegible]ovement, is reported. Neither agent
reduced [illegible]cid (GA), but RF increased GABA levels.
A trial [illegible] [illegible]scontinued because of severe lethargy
and
vomiting.
ABEX The pati[illegible] [illegible]ntil 11 mth of age when he had a 3 day
episode [illegible] low-grade fever hat led to seizures
and
coma. Th[illegible] viral encephalitis. After this he lost
some dev[illegible] [illegible]ypotonic and had choreoathetoid
movement[illegible] [illegible]is skills but at 24 mth, he had a 2nd
viral-li[illegible] [illegible]th severe lethargy and vomiting. CT
showed b[illegible] [illegible]y. He continued to lose motor skills
and
at 45 m[illegible] [illegible] sturing. He was unable to sit without
support, [illegible]ypotonia and choreoathetosis was noted
on volit[illegible] [illegible]s **dysarthritis**; IQ was 50-55.
Glutaric [illegible] [illegible]nosed on finding peaks of GA (9-24
ug/ml) a[illegible] [illegible]MS of urine specimens. Plasma GA was 11
ug/ml. [illegible] [illegible]ed by finding less than 1% of normal

activity ... ogenase in fibroblasts. Magnetic resonane
imaging ... lobe atrophy and fibrosis and
bilateral
hyperluc ... ct of the caudate nucleus. He was put
on
a protei ... ceived 100 mg/day p.o. RF for 1 wk, 100
mg/kg/da ... RF+CT continuously. Before treatment,
CSF leve ... GABA was decreased and HVA and
HIAA wer ... ect on GA but raised **GABA** to
normal ... inary short-chain acylcarnitine; total
plasma ... normal. Long term RF+CT treatment was
associat ... improvement and the rapid progression of
the neur ... (E54/RSV) (M.L.B.).
ABEX. ... t support, had truncal and nuchal
hypotoni ... us noted on volitional movement. Speech
was **dys** ... Glutaric acidemia type I was
diagnose ... (9-24 ug/ml) and 3-OH-glutarate on
GLC/MS. ... ay p.o. CT for 1 wk, then RF+CT
continue ... SF levels of GA were elevated,
GABA wa ... AA were normal; RF had no effect
on GA bu ... evels. CT increased urinary
short-c ... plasma CT rose from subnormal to
normal.
Long te ...

L10 ANSWER ... T 2001 DERWENT INFORMATION LTD
ACCESSION NUM ... S
TITLE: ... ent Disorders.
AUTHOR: ... Barbeau A
LOCATION: ... ada
SOURCE: ... oxicol. (27, 113-36, 1987) 169 Ref.
... ISSN: 0362-1642
AVAIL. OF DOC. ... iology, Clinical Research Institute of
... Quebec, Canada H2W 1R7.

LANGUAGE:
DOCUMENT TYPE:
FIELD AVAIL.:
FILE SEGMENT:
AN 1987-24 ...
AB Drugs a ... s are reviewed. The treatment of
Parkinso ... vodopa is discussed, and problems of
long
term us ... f levodopa are mentioned. The use of
anticho ... e drugs, amantidine, bromocriptine and
other d ... ised. The treatment of dystonic
syndrom ... , Gilles de la Tourette syndrome and
Wilson's ... d.
ABEX Aspe ... h levodopa are discussed. Levodopa is
given w ... de which reduce the peripheral but not
the cen ... nal involuntary movements are a
particu ... levodopa therapy; altering the
levodopa
dosage ... ne, methysergide and amitriptyline have
been o ... ymptoms. Levodopa may cause melanoma.
The use ... trihexyphenidyl HCl, procyclidine HCl,
cycrimi ... propazine HCl, bornaprine HCl,
methixe ... , chlorphenoxamine HCl and
orphenadrine
HCl is ... have fewer side effects than
anticho ... of the antiparkinsonian effect of

amanti: ...ocriptine, lisuride and pergolide are useful ...% receptor agonists. Lergotrile mesylate and mes... toxic. Other drugs with possible useful: ..., threodihydroxyphenylserine, (+)-4-p... ...ne, propranolol and clonazepam. The treatme... ...Huntington's disease, Gilles de la **Touretti** ...sease is briefly discussed, with referer... ...nazine, trihexyphenidyl, ethopropazine, cholin... ...benztropine, isoniazid, sodium valpro... ...gamma-vinyl **GABA**, gaboxadol, flupher... ...mine, lithium carbonate, nitrous oxide, clonid... ...and zinc sulfate or acetate. (E33/JB) ABEX. ...reodihydroxyphenylserine, (+)-4-propyl 9-hydr... ...ol and clonazepam. The treatment of dyston... ...disease, Gilles de la **Tourette** syndro... ...briefly discussed, with reference to halope... ...yphenidyl, ethopropazine, choline, arecol... ...e, isoniazid, sodium valproate, gamma-... ...GABA**, gaboxadol, fluphenazine, reserp... ...carbonate, nitrous oxide, clonidine, penici... ...fate or acetate. (E33/JB)

L10 ANSWER ... 2001 BIOSIS DUPLICATE 7
ACCESSION NU...
DOCUMENT NUM...
TITLE: ...EATMENT OF EPILEPSY A DOUBLE-BLIND ...TUDY.
AUTHOR(S): ...GALIMBERTI C A; HARDENBERG J; ORWIN J;
CORPORATE SO... ...MONDINO," VIA PALESTRO 3, 27100 PAVIA,
SOURCE: ... 7 (6), 717-723. ...: 0013-9580.
FILE SEGMENT:
LANGUAGE:

AB The eff... ...gabatrin (.gamma.-vinyl **GABA**, GVG), g... ...adult outpatients with severe drug-re... ...artial seizures), were studied using a double-... ...crossover design. The study consisted of two 7-w... ...gabatrin and placebo were administered in rand... ...g twice daily for patients weighing .ltoreq... ...ly for patients weighing > 65 kg. Three patient... ...dy, two reasons unrelated to treatment and one... ...of vertigo, headache, **dysarthria**, and a... ...y when vigabatrin was stopped (3 g daily). ...available for analysis showed a decreas... ...izures as compared with the placebo period. ...reduction in seizure frequency and 4 of the ... Both the total number of seizures and the numb... ...e significantly reduced by vigabatrin ($p < 0.$... ...dropped out were severe adverse effects ...reported unwanted effect were mild drowsi... ...n patients on vigabatrin and in one on placeb... ..., were also seen with six patients who report... ...being while receiving vigabatrin as compar... ...cebo period. No consistent changes in electro... ...ephalogram (EEG), and visual-, auditor... ...potentials were seen during the study.

Serum [illegible] ulsants remained unchanged, with the
excepti[illegible] enytoin during vigabatrin in the only
phenytc[illegible] ude that add-on treatment with
vigabat[illegible] olerated in adult patients with
drug-re[illegible]

AB The effi[illegible] igabatrin (.gamma.-vinyl **GABA**,
GVG), [illegible] 3 adult outpatients with severe
drug-re[illegible] artial seizures), were studied using.

. pati[illegible] study, two reasons unrelated to
treatm[illegible] pearance of vertigo, headache,
dysarthr[illegible] ded rapidly when vigabatrin was
stopped[illegible] 20 patients available for analysis.

L10 ANSWER [illegible] 2001 DERWENT INFORMATION LTD
ACCESSION NU[illegible] P S
TITLE: [illegible]
AUTHOR: [illegible] n E
LOCATION: [illegible]
SOURCE: [illegible] 05-22, 1986) 3 Fig. 9 Tab. 177 Ref.
[illegible] SSN: 0037-1777
AVAIL. OF DO[illegible] versitaire de Psychiatrie, Centre
[illegible] e Nacre, 14033 CAEN CEDEX, France.
LANGUAGE:
DOCUMENT TYP[illegible]
FIELD AVAIL[illegible]
FILE SEGMEN[illegible]
AN 19[illegible]
AB Anxiol[illegible] icular reference to their chemical
struct[illegible] ity and mode of action,
pharma[illegible] eractions, side effects and therapeutic
uses. [illegible] ficacy the benzodiazepines (BZ) are
rapidl[illegible] ic drugs.
ABEX BZ [illegible] am, chlordiazepoxide, clobazam,
clor[illegible] m (DZ), loflazepate, lorazepam,
me[illegible] tofisopam are rapidly absorbed by the
GI tra[illegible] s easily into the CNS, where they bind
to spe[illegible] oupled to **GABA** receptors and
CL lor[illegible] ics, muscle relaxants and
antico[illegible] gent is dependent on pharmacokinetics
and pl[illegible] e anxiolytics including benzoctamine,
captod[illegible] diol, hydroxyzine, medifoxamine,
mepho[illegible] lpentynol, methaqualone, mephenesin,
oxy[illegible] octamide may also be used.
Ba[illegible] chlorpromazine, amitriptyline,
am[illegible] idine and alcohol also have anxiolytic
act[illegible] exics, salbutamol, yohimbine, caffeine
ant[illegible] c. BZ undergo hepatic metabolism with
the[illegible] bolites e.g. desmethyl DZ and renal
exc[illegible] oms of BZ induced sedation are fatigue,
som[illegible] tigo, **dysarthria**, ataxia and
obt[illegible] ne risk of sedation. Other interactions
wi[illegible] picin, cimetidine, disulfuram, p.o.
co[illegible] been reported. The BZ have been
as[illegible] rome. In the future it may be possible
to[illegible] th the specific receptor antagonist
RO-[illegible] tiques)
ABEX. [illegible] lic pass easily into the CNS, where
they

bi· are coupled to **GABA** receptors
an olytics, muscle relaxants and
an gent is dependent on pharmacokinetics
an ethyl DZ and renal excretion as
gl· uced sedation are fatigue, somnolence,
we· **hria**, ataxia and obnubilation;
al· ation. Other interactions with tobacco,
ba· ine, disulfuram, p.o. contraceptives
an·

L10 ANS· 2001 ELSEVIER SCI. B.V.DUPLICATE 8
ACCESSIO·
DOCUMENT ·
TITLE: eatment of tardive dyskinesia and other

AUTHOR: n J.E.; Simpson M.L.; et al.
CORPORAT· psychopharmacology, Palo Alto Veterans
cal Center, Palo Alto, CA, United
States
SOURCE: ry, (1985) 20/8 (888-893).

COUNTRY:
DOCUMENT
FILE SEG· ıture Index

nd Neurosurgery
y

LANGUAGE:
AB We · of gamma-vinyl-**GABA** (GVG) in
nin· dyskinesia, one with Meige syndrome,
and
one ardive dyskinesia patients
com· and, as a group, demonstrated
sig· a scores. Four of these five tardive
dys· lly evident improvement, with
app· kinetic symptoms. Other patients had no
cli· atients had transient exacerbation of
psy· withdrawal of GVG, and one patient
exp· al episodes. Our results suggest that
GAB· treating patients with tardive
dys·
AB We · of gamma-vinyl-**GABA** (GVG) in
nin· dyskinesia, one with Meige syndrome,
and
one ardive dyskinesia patients
com· and, as a group, demonstrated
sig· a scores.. . .

L10 AN· T 2001 INIST-CNRS. ALL RIGHTS RESERVED.
ACCESSIO· PASCAL
TITLE (I· BA treatment of tardive dyskinesia and
disorders
AUTHOR: HORNTON J. E.; SIMPSON M. L.; BERGER P.
M. J.
CORPORAT· t., Palo Alto CA, United States
SOURCE: chiatry, (1985), 20(8), 888-893, refs.
2

DOCUMENT

BIBLIOGR
COUNTRY:
LANGUAGE:
AVAILABI
AN 19
ABFR Ana -vinyl-**GABA** dans le traitement
des drome de Meige et du syndrome de
Tou
ABFR Ana -vinyl-**GABA** dans le traitement
de drome de Meige et du syndrome de
Tou

L10 ANS T 2001 ELSEVIER SCI. B.V.DUPLICATE 9
ACCESSIO
DOCUMENT
TITLE: reatment of hyperkinetic extrapyramidal

AUTHOR: E.; Braendgaard H.
CORPORAT ology, Aarhus Municipal Hospital,
DK-8000

SOURCE: candinavica, (1985) 72/3 (341-343).

COUNTRY:
DOCUMENT
FILE SEG ture Index
nd Neurosurgery
gy

LANGUAGE:
AB The -receptor agonist, progabide,
to y movements was evaluated in a preliminary
ope 1(males and 7 females, aged 10-78 years,
with ers were included in the study. Daily
dos) to 3600 mg (median 2400 mg)
cor an 45 mg/kg), while the duration of
tre s. Improvement, with a reduction of
inv %, occurred in two of four patients
with
Gil , and in two of three patients
wit os, while no consistent beneficial
eff tients with Huntington's chorea,
pos on dystonia, tardive dyskinesia, action
tre o-branchio-respiratory myoclonus.
AB The -receptor agonist, progabide,
to ovements was evaluated in a preliminary
ope males and. . . weeks. Improvement,
wit ovements exceeding 25%, occurred in two
of l **Tourette**'s syndrome, and in
two a xic intention myoclonus, while no
con registered in ten. . .

L10 ANS 2001 BIOSIS DUPLICATE 10
ACCESSIC
DOCUMENT
TITLE: YPE I PRESENTING WITH HYPOGLYCEMIA.
AUTHOR(S SS G J A I
CORPORAT , UNIV. LONDON, 30 GUILFORD ST., LONDON

SOURCE: IS, (1984) 7 (3), 122-124.
0141-8955.

FILE SEC
LANGUAGE:
AB A c enase deficiency (type I glutaric
aci subdural hydromas, and progressive
cho e diagnosis was made when she
was at the age of 3.5 yr. Temporary
adr also noted. Three years after diagnosis
the oglycemia have resolved and treatment
wit ABA analog, has prevented any
fur
AB A c enase deficiency (type I glutaric
aci subdural hydromas, and progressive
cho e diagnosis was made when she
was at the age of 3.5 yr. Temporary
adr also noted. Three years after
dia y and hypoglycemia have resolved and
tre resal, a **GABA** analog, has
pre deterioration.

L10 ANS 2001 BIOSIS
ACCESSIC
DOCUMEN
TITLE: AMMA AMINO BUTYRIC-ACID AND ADENOSINE
IN
FLUID IN PROGRESSIVE MYO CLONUS
EPILEPSY
IES.
AUTHOR(S K; FREDHOLM B B; HARE T A
CORPORA LTAVUORENPENGER 10 A, SF-00170 HELSINKI
SOURCE: 40 (10), 623-625.
C003-9942.
FILE SEG
LANGUAGE:
AB Pro without Lafora's bodies (PME) is a rare
inh ntly in Finland, where the incidence is
1 c s fatal disease is characterized by
no ive stimulus-sensitive myoclonus,
ata nd mal seizures and loss of
ce ations of **GABA** in the CSF
ave .+-. SE) in 8 patients with PME,
co in 10 control patients. The
co mol/ml vs. 17 pmol/ml), inosine (560
pm nthine (6.2 nmol/ml vs. 6.1 nmol/ml)
we and in controls.
AB. e/20,000-30,000 children. This fatal
dis early development, progressive
st ia, **dysarthria**, occasional
gr bellar Purkinje cells. Concentrations
of 10 pmol/ml (mean .+-. SE) in
8 135 .+-.. .

L10 A 2001 DERWENT INFORMATION LTD
ACCESSI
TITLE: e's Syndrome.
AUTHOR:
LOCATIO States
SOURCE: , 501, 1982)
ISSN: 0272-4391
AVAIL. C ry, Texas Tech. University Regional

er, El Paso, Texas, U.S.A.

LANGUAGE
DOCUMENT
FIELD AV
FILE SEG
AN 19
AB A henobarbital was gradually changed
to
cl his Gilles de la **Tourette**
sy his case, successful, and should be
co mechanism of CP action in this
ca could be due to the inhibitory effect
it
he litating activity. (congress).
ABEX A Tourette syndrome had been treated
with
cl improvement of the tics and the
al dication of phenobarbital was gradually
de ased. Improvement in tics and few
al initial CP treatment. Reduction of CP
d tics and some grunting sounds.
In g at bedtime produced remarkable
control
of within normal limits and he has been
ma e during the past 8-mth period.
AB. ived phenobarbital was gradually
cl treatment of his Gilles de la
T as, in this case,
s ed for clinical trial. The mechanism
o understood, but could be due to the
i NS, and its **GABA** facilitating
a

L10 AN 2001 BIOSIS
ACCESSIO
DOCUMENT
TITLE: CONSIDERATIONS AND A PHARMACOLOGICAL
OGY OF THE EXTRAPYRAMIDAL SYSTEM.

AUTHOR( ) C A; ANGELINI L
CORPORA IC INFANTILE, IST. NEUROLOGICO C.
BESTA,

SOURCE: A VOL, (1982 (RECD 1983)) 2 (4),

FILE SE
LANGUAG
IT Mi IC **GAMMA AMINO**
ACTIVITY STIFFNESS
E A **TOURETTE** SYNDROME BALLISM

L10 A 1 DERWENT INFORMATION LTD
ACCESSI
TITLE: S OF THE INITIAL PERIOD OF STUTTERING
IN

AUTHOR:
LOCATIO
SOURCE: (77, NO.10, 1555-59, 1977)

IT G[illegible] TI .PHENYLMETHANE BENACTYZINE =
A[illegible] = [illegible]ULEPTIL THIORIDAZINE = MELLERIL
ETC.
T[illegible] PSYCHIATRY **STUTTERING**
P[illegible] ES

L10 A[illegible] 2001 DERWENT INFORMATION LTD
ACCESSI[illegible]
TITLE: [illegible]TROPIC AGENT./RUSS./.
AUTHOR: [illegible] M G; ALTSHULER R A
LOCATIO[illegible]
SOURCE: [illegible] (9, NO.9, 60-62, 1975)
IT G[illegible] [illegible].HYPOTENSIVE
P[illegible] RHATMENT OF NEUROLOGY APHASIA
D[illegible] SSION CASES REVIEW 25 REF.
H[illegible] V [illegible] AL-DISORDER

L10 A[illegible] 2001 DERWENT INFORMATION LTD
ACCESSI[illegible]
TITLE: [illegible] Disease. Basal Ganglia Disease.
AUTHOR:
LOCATIO[illegible]
SOURCE: [illegible]8, 1141-47) 4 Fig. 41 Ref.
[illegible]SN: 0140-6736
AVAIL. [illegible] Neurology, Institute of Psychiatry
[illegible] Hospital Medical School, London SE5 8AF,

LANGUAG[illegible]
DOCUMEN[illegible]
FIELD A[illegible]
FILE SE[illegible]
AN 19[illegible]
AB Bi[illegible] ganglia diseases are reviewed with
pa[illegible]'s disease (PD) and Huntington's chorea
(H[illegible]
ABEX Th[illegible] of the basal ganglia is outlined. Core
pa[illegible] f the pigmented neuronal systems,
mainly
ir[illegible] eruleus. The histological marker is
the
Le[illegible] ion in affected neurons. Levodopa
al[illegible] rovement, remains the mainstay of
th[illegible] d in combination with carbidopa
(S[illegible]). Bromocriptine is also effective.
Ac[illegible] -binding) receptors. Levodopa side
ef[illegible] tic or affective episodes. The
pa[illegible] rebral cortex and basal ganglia. Its
et[illegible] nic acid has been postulated to play
so[illegible] fective therapy for this invariably
fa[illegible] reduced to some extent by dopamine
an[illegible] zines). Drugs aimed to prevent
GA[illegible] isoniazid) or **GABA**
ag[illegible] ly unsuccessful, as have
therapeu
at[illegible] ilocarpine. Other movement
disorder
ve[illegible] hy-drager syndrome and dyskinesias such
as[illegible] ic myoclonus (responds to
5-[illegible] de la **Tourette**'s disease,
es[illegible], propranolol, primidone and

isc ... eimer's disease.
ABEX. . ... chorea can be reduced to some
ext ... benazine, phenothiazines). Drugs
ain ... ium valproate and
isc ...) have been generally
uns ... empts with choline, arecoline or
pil ... very briefly. . . considered
inc ... nesias such as Lesch-Nyhan
syndrome,
pos ... -hydroxytryptophan), chorea, Gilles
de ... remor (sensitive to
alc ... soniazid), torsion dystonia and
Al:

=> log h
COST IN U

	SINCE FILE ENTRY	TOTAL SESSION
FULL EST	228.17	232.43

DISCOUNT	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCR	-2.35	-2.35